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Running	title:	Integrative	analyses	of	lung	neuroendocrine	neoplasms		
Abstract	The	worldwide	 incidence	of	pulmonary	carcinoids	 is	 increasing,	but	 little	 is	known	about	 their	molecular	 characteristics.	 Through	 machine	 learning	 and	 multi-omics	 factor	 analysis,	 we	compare	and	contrast	the	genomic	profiles	of	116	pulmonary	carcinoids	(including	35	atypical),	75	 large-cell	 neuroendocrine	 carcinomas	 (LCNEC),	 and	 66	 small-cell	 lung	 cancers.	 Here	 we	report	 that	 the	 integrative	 analyses	 on	 257	 lung	 neuroendocrine	 neoplasms	 stratify	 atypical	carcinoids	 into	 two	 prognostic	 groups	 with	 a	 10-year	 overall	 survival	 of	 88%	 and	 27%,	respectively.	 We	 identify	 therapeutically	 relevant	 molecular	 groups	 of	 pulmonary	 carcinoids,	suggesting	DLL3	and	the	immune	system	as	candidate	therapeutic	targets;	we	confirm	the	value	of	OTP	 expression	 levels	 for	 the	 prognosis	 and	 diagnosis	 of	 these	 diseases,	 and	we	 unveil	 the	group	 of	 supra-carcinoids.	 This	 group	 comprises	 samples	 with	 carcinoid-like	 morphology	 yet	with	 molecular	 and	 clinical	 features	 of	 the	 deadly	 LCNEC,	 validating	 the	 previously	 proposed	molecular	link	between	the	low-	and	high-grade	lung	neuroendocrine	neoplasms.			 	
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Introduction	According	 to	 the	 WHO	 classification	 from	 20151	 and	 a	 recent	 IARC-WHO	 expert	 consensus	proposal2,	 pulmonary	 carcinoids	 are	 low-grade	 typical	 and	 intermediate-grade	 atypical	 well-differentiated	 lung	 neuroendocrine	 tumours	 (LNETs)	 that	 belong	 to	 the	 group	 of	 lung	neuroendocrine	 neoplasms	 (LNENs),	 which	 also	 includes	 the	 high-grade	 and	 poorly	differentiated	small-cell	 lung	cancer	(SCLC)	and	large-cell	neuroendocrine	carcinomas	(LCNEC).	Pulmonary	 carcinoids	 are	 rare	malignant	 lesions,	which	 annual	 incidence	 has	 been	 increasing	worldwide,	 especially	 at	 the	 advanced	 stages3.	 Pulmonary	 carcinoids	 account	 for	 1–2%	 of	 all	invasive	 lung	 malignancies:	 typical	 carcinoids	 exhibit	 good	 prognosis,	 although	 10-23%	metastasize	to	regional	lymph	nodes,	resulting	in	a	5-year	overall	survival	rate	of	82-100%.	The	prognosis	 is	worse	 for	atypical	 carcinoids,	with	40-50%	presenting	metastasis,	 reducing	 the	5-year	overall	survival	rate	to	50%.	Contrary	to	pulmonary	carcinoids,	most	of	which	are	eligible	for	upfront	surgery	at	the	time	of	diagnosis3,	LCNEC	and	SCLC	require	upfront	aggressive,	multimodal	treatment	for	most	of	the	patients.	Due	to	these	differences	in	clinical	management	and	prognosis,	the	accurate	diagnosis	of	these	diseases	is	critical.	However,	there	is	still	no	consensus	on	the	optimal	approach	for	their	differential	 diagnosis2;	 the	 current	 criteria,	 based	 on	 morphological	 features	 and	immunohistochemistry,	 are	 imperfect	 and	 inter-observer	 variations	 are	 common,	 especially	when	 separating	 typical	 and	 atypical	 carcinoids4,	 as	well	 as	 atypical	 carcinoids	 from	LCNEC	 in	small	 biopsies5.	 Ki67	 protein	 immune-reactivity	 has	 been	 suggested	 as	 a	 good	 marker	 of	prognosis	 in	 LNENs	 as	 a	 whole,	 and	 of	 differential	 diagnosis	 between	 carcinoids	 and	 SCLC6,7,	whereas	 this	marker	 does	 not	 faithfully	 follow	 the	 defining	 histological	 criteria	 of	 typical	 and	atypical	carcinoids4.	The	difficulties	in	finding	good	markers	to	separate	these	diseases	might	be	due	 to	 the	 limited	 amount	 of	 comprehensive	 genomic	 studies	 available	 for	 SCLC,	 LCNEC,	 and	typical	carcinoids,	and	the	complete	lack	of	such	studies	for	atypical	carcinoids8.	In	addition,	such	studies	would	also	be	needed	to	validate	the	recent	proposed	molecular	link	between	pulmonary	carcinoids	and	LCNEC9,10.	In	this	study,	we	provide	a	comprehensive	overview	of	the	molecular	traits	of	LNENs—with	a	particular	focus	on	the	understudied	atypical	carcinoids—in	order	to	identify	the	mechanisms	underlying	 the	 clinical	 differences	 between	 typical	 and	 atypical	 carcinoids,	 to	 understand	 the	suggested	molecular	link	between	pulmonary	carcinoids	and	LCNEC,	and	to	find	new	candidates	for	the	diagnosis	and	treatment	of	these	diseases.		
Results	
Data	We	have	generated	new	data	(genome,	exome,	transcriptome	and	methylome)	for	63	pulmonary	carcinoids	(including	27	atypical)	and	20	LCNEC.	In	order	to	perform	comparative	analyses,	we	have	reanalysed	published	data	for	74	pulmonary	carcinoids11,	75	LCNEC12,	and	66	SCLC13,14	().	Taken	 together,	 we	 have	 performed	 multi-omics	 integrative	 analyses	 on	 116	 pulmonary	carcinoids	 (including	 35	 atypical),	 75	 LCNEC,	 and	 66	 SCLC	 (Supplementary	 Figure	 1;	
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Supplementary	Table	1).	All	new	specimens	were	collected	 from	surgically	resected	tumours,	applying	 local	 regulations	 and	 rules	 at	 the	 collecting	 site,	 and	 including	 patient	 consent	 for	molecular	analyses	as	well	as	 collection	of	de-identified	data,	with	approval	of	 the	 IARC	Ethics	Committee.	 These	 samples	 underwent	 an	 independent	 pathological	 review.	 For	 the	 typical	carcinoids	and	LCNEC,	on	which	methylation	analyses	were	performed,	the	DNA	came	from	the	samples	 included	 in	 already	published	 studies4,11-15,	 for	which	pathological	 review	had	already	been	done.	
	
Molecular	groups	of	pulmonary	carcinoids	and	LCNEC	We	performed	 an	unsupervised	 analysis	 of	 the	 expression	 and	methylation	data	 of	 the	 LNENs	(i.e.,	 110	 pulmonary	 carcinoids	 and	 72	 LCNEC)	 using	 the	 Multi-Omics	 Factor	 Analysis	implementation	 of	 the	 group	 factor	 analysis	 statistical	 framework	 (Software	 MOFA)16	 (MOFA	LNEN;	Figure	1A;	Supplementary	Figures	2	and	3;	).	We	identified	five	latent	factors	explaining	more	 than	 2%	 of	 the	 variance	 in	 at	 least	 one	 dataset,	 and	 among	 them,	 three	 latent	 factors	provided	 consistent	 groups	 of	 samples	 with	 similar	 expression	 and	 methylation	 profiles	 (i.e.,	clusters).	MOFA	latent	factors	one	(LF1)	and	two	(LF2)	explained	a	total	of	45%	and	34%	of	the	variance	 in	 methylation	 and	 expression,	 respectively,	 and	 were	 both	 associated	 with	 survival	(Supplementary	 Figure	 4).	 Using	 consensus	 clustering	 on	 these	 two	 latent	 factors	 (which	explained	 most	 of	 the	 variation	 and	 thus	 carried	 the	 most	 biological	 signal;	 Supplementary	
Figures	5-7;	Supplementary	Tables	2-3),	we	 identified	 three	 clusters,	 each	of	 them	enriched	for	 samples	 of	 one	 of	 the	 three	 histopathological	 types	 (Figure	 1A).	 Cluster	 Carcinoid	 A	 was	enriched	 for	 typical	carcinoids	(75%;	Fisher’s	exact	 test	p-value<2.2x10-16);	cluster	Carcinoid	B	was	 enriched	 for	 atypical	 carcinoids	 (54%;	 Fisher’s	 exact	 test	 p-value<2.2x10-16)	 and	 male	patients	 (79%;	 Fisher’s	 exact	 test	 p-value=1.6x10-9);	 and	 cluster	 LCNEC	 included	 92%	 of	 the	histopathological	 LCNEC	 (Fisher’s	 exact	 test	 p-value<2.2x10-16).	 Note	 that	 clustering	 based	 on	LF1	to	LF5,	weighted	by	their	proportion	of	variance	explained,	leads	to	the	exact	same	clusters	(Supplementary	Figure	8).	To	 assess	 whether	 the	 current	 histopathological	 classification	 could	 be	 improved	 by	 the	combination	of	molecular	and	morphological	 characteristics,	we	undertook	a	machine-learning	(ML)	 analysis.	 To	 do	 so,	 we	 combined	 the	 predictions	 from	 two	 independent	 random	 forest	classifications,	 based	 on	 only-expression	 or	 only-methylation	 data.	 Using	 two	 independent	models	allowed	the	inclusion	of	samples	for	which	only	one	of	these	datasets	was	available,	thus	maximizing	 the	 power	 of	 subsequent	 analyses	 (Figure	 1B;	 Supplementary	 Figure	 9	 for	 an	alternative	 analysis	 based	 on	 both	 ‘omic	 datasets	 simultaneously,	 but	 restricted	 to	 fewer	samples).	 In	order	 to	avoid	overfitting	 the	data,	we	performed	a	 leave-one-out	cross	validation	with	 feature	 filtering	 and	 normalization,	 learned	 from	 the	 training	 set	 and	 applied	 to	 the	 test	sample.	 To	 identify	 intermediate	 profiles,	 we	 defined	 a	 prediction	 category,	 Unclassified,	 for	samples	 which	 probability	 ratio	 between	 the	 two	 most	 probable	 classes	 was	 close	 to	 1.	 We	present	in	Figure	1B	the	results	for	a	cut-off	ratio	of	1.5,	and	show	in	Supplementary	Figure	10	the	 robustness	 of	 our	 results	 with	 regard	 to	 this	 ratio.	 Ninety-six	 per	 cent	 of	 the	 carcinoids	
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predicted	as	typical	by	the	ML	were	in	cluster	Carcinoid	A	(Figure	1A).	Similarly,	the	majority	of	ML-predicted	atypical	carcinoids	(87%)	belonged	to	cluster	Carcinoid	B.	We	 selected	 the	 ML-prediction	 groups	 with	 more	 than	 10	 samples	 (gathering	 the	unclassified	 samples	 in	 one	 single	 group)	 and	 compared	 their	 overall	 survival	 using	 Cox’s	proportional	hazard	model	(coloured	groups	in	Figure	1B).	The	machine	learning	trained	on	the	histopathology,	 stratified	 atypical	 carcinoids	 into	 two	 prognostic	 groups:	 the	 good-prognosis	group	 (atypical	 reclassified	 as	 typical,	 in	 pink	 in	Figure	1B-C)	with	 a	 10-year	 overall	 survival	similar	to	that	of	samples	confirmed	by	ML	as	typical	carcinoids	(in	black	in	Figure	1B-C;	88%	and	 89%,	 respectively;	 Wald	 test	 p-value=0.650);	 and	 the	 bad-prognosis	 group	 (atypical	predicted	 as	 atypical,	 in	 red	 in	Figure	1B-C)	with	 a	 10-year	 overall	 survival	 similar	 to	 that	 of	samples	confirmed	by	ML	as	LCNEC	(in	blue	 in	Figure	1B-C;	27%	and	19%	respectively;	Wald	test	 p-value=0.574;	 see	 also	 Supplementary	 Figure	 11).	 Machine-learning	 analyses	 based	 on	other	 features	 such	as	 combined	expression	and	methylation	data	 (Supplementary	Figure	9),	MOFA	 latent	 factors	 (Supplementary	 Figure	 12A),	 and	 Principal	 Component	 Analyses	 (PCA)	Principal	Components	explaining	more	than	2%	of	 the	variance	(Supplementary	Figure	12B),	led	to	qualitatively	similar	results.		
Atypical	carcinoids	with	LCNEC	molecular	characteristics	Six	atypical	carcinoids	clustered	with	LCNEC	in	the	MOFA	LNEN	(supra-carcinoids;	Figure	1A).	Consistent	with	this	clustering,	this	group	displayed	a	survival	similar	to	the	other	samples	in	the	LCNEC	cluster	(10-year	overall	survival	of	33%	and	19%,	respectively;	Wald	test	p-value=0.574;	
Figure	 2A).	 The	 observed	 molecular	 link	 appear	 to	 be	 between	 supra-carcinoids	 and	 LCNEC	rather	 than	 with	 SCLC,	 as	 shown	 by	 PCA	 and	 MOFA	 including	 expression	 data	 for	 51	 SCLC	(Supplementary	Figure	6	and	Supplementary	Figure	13,	respectively).	These	 samples	originated	 from	 three	different	 centres	 (two	 from	each),	 and	 included	 two	previously	published	samples	(S01513	and	S01522)11,	implying	that	this	observation	is	unlikely	to	be	the	result	of	a	batch	effect.	The	limited	number	of	supra-carcinoids	did	not	allow	to	explore	etiological	 links;	however,	 it	 is	of	note	 that	one	of	 them	(LNEN005)	belonged	 to	a	patient	with	professional	exposure	to	asbestos	(which	is	known	to	cause	mesothelioma)17	(Table	1),	and	the	tumour	 harboured	 a	 splicing	 BAP1	 somatic	 mutation	 (a	 gene	 frequently	 altered	 in	mesothelioma)18.	 This	 sample	 showed	 the	 highest	 mutational	 load	 (37	 damaging	 somatic	mutations;	Supplementary	Table	4).	Gene	Set	Enrichment	Analyses	(GSEA)	of	mutations	in	the	hallmarks	 of	 cancer	 gene	 sets	 19,20,	 showed	 a	 significant	 enrichment	 for	 the	 hallmark	 evading	growth	 suppressor	 (q-value=0.0213;	 Figure	 2B;	 Supplementary	 Table	 5),	 while	 genome	instability	 and	mutation	were	 significant	 at	 the	10%	False-Discovery-Rate	 (FDR)	 threshold	 (q-value=0.0970;	 Figure	 2B;	 Supplementary	Table	 5).	We	 had	 access	 to	 the	 Haematoxylin	 and	Eosin	 (H&E)	 stain	 for	 three	 of	 these	 supra-carcinoids,	 on	 which	 the	 pathologists	 discarded	misclassifications	with	LCNEC,	SCLC,	or	mesothelioma	in	the	case	of	the	asbestos-exposed	BAP1-mutated	sample	(Figure	2C;	Table	1).	
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While	generally	similar	to	LCNEC,	and	albeit	based	on	small	numbers,	the	supra-carcinoids	appeared	to	have	nonetheless	some	distinct	genomic	features	based	on	genome-wide	expression	and	 methylation	 profiles	 (Figure	 2D).	 Supra-carcinoids	 displayed	 higher	 levels	 of	 immune	checkpoint	genes	(both	receptors	and	ligands;	Figure	2E),	and	also	harboured	generally	higher	expression	 levels	 of	 MHC	 class	 I	 and	 II	 genes	 (Figure	 2E;	 Supplementary	 Figure	 14).	Interestingly,	the	interferon-gamma	gene—a	prominent	immune-stimulator,	 in	particular	of	the	MHC	class	I	and	II	genes—also	showed	high	expression	levels	in	these	samples	(Supplementary	
Figure	14).	The	differences	in	immune	checkpoint	gene	expression	levels	between	groups	were	not	 explained	 by	 the	 amount	 of	 infiltrating	 cells,	 as	 estimated	 by	 deconvolution	 of	 gene	expression	 data	 with	 software	 quanTIseq	 (Figure	 2F,	 left	 panel).	 However,	 supra-carcinoids	contained	 the	highest	 levels	of	neutrophils	 (greater	 than	 the	3rd	quartile	of	 the	distributions	of	neutrophils	 in	 the	other	groups;	Figure	2F,	right	panel).	Permutation	 tests	 showed	 that	 these	levels	were	significantly	higher	than	in	other	carcinoid	groups	and	in	SCLC,	but	not	than	in	LCNEC	(Supplementary	 Figure	 15).	 Concordantly,	 GSEA	 showed	 that	 MOFA	 LNEN	 LF1	 (separating	LCNEC	 and	 supra-carcinoids	 from	 the	 other	 carcinoids)	 was	 significantly	 associated	 with	neutrophil	chemotaxis	and	degranulation	pathways	(Supplementary	Table	6).	By	contrast,	no	such	 association	was	 observed	 in	 the	MOFA	 performed	 only	 on	 carcinoids	 and	 SCLC	 samples	(Supplementary	Figure	6C;	Supplementary	Figure	13C;	Supplementary	Table	6).		
Mutational	patterns	of	pulmonary	carcinoids	In	a	previous	study,	mainly	including	typical	carcinoids,	we	detected	MEN1,	ARID1A,	and	EIF1AX	as	significantly	mutated	genes11.	We	also	found	that	covalent	histone	modifiers	and	subunits	of	the	 SWI/SNF	 complex	 were	 mutated	 in	 40%	 and	 22.2%	 of	 the	 cases,	 respectively.	 Genomic	alterations	in	these	genes	and	pathways	were	also	seen	in	the	new	samples	included	in	this	study	(Figure	 3A;	 Supplementary	 Figure	 16;	 Supplementary	 Table	 4).	 Apart	 from	 the	 above-mentioned	 genes,	 ATM,	 PSIP1,	 and	 ROBO1	 also	 showed	 some	 evidence,	 among	 others,	 for	recurrent	mutations	 in	 pulmonary	 carcinoids	 (Figure	3A).	 In	 addition	 to	 point	mutations	 and	small	 indels,	 the	 ARID2,	 DOT1L,	 and	 ROBO1	 genes	 were	 also	 altered	 by	 chimeric	 transcripts	(Figure	3B).	MEN1	was	also	inactivated	by	genomic	rearrangement	in	a	carcinoid	sample	with	a	chromothripsis	 pattern	 affecting	 chromosomes	 11	 and	 20	 (Figure	 3C).	 The	 full	 lists	 of	somatically	 altered	 genes,	 chimeric	 transcripts,	 and	 genomic	 rearrangements	 are	 presented	 in	
Supplementary	 Tables	 4,	7,	 and	 8,	 respectively.	 Of	 note,	MEN1	 mutations	 were	 significantly	associated	 with	 the	 atypical	 carcinoid	 histopathological	 subtype	 (Fisher’s	 exact	 test	 p-value=0.0096),	as	well	as	MOFA	LNEN	LF2.		
Altered	pathways	in	pulmonary	carcinoids	The	 third	 latent	 factor	 from	 the	 MOFA	 LNEN	 accounted	 for	 8%	 and	 6%	 of	 the	 variance	 in	expression	and	methylation,	respectively,	but	unlike	LF1	and	LF2,	LF3	was	not	associated	with	patient	survival	(Supplementary	Figure	4).	The	molecular	variation	explained	by	LF3	appeared	to	capture	different	molecular	profiles	within	cluster	Carcinoid	A	(Supplementary	Figure	13B).	
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We	 therefore	 undertook	 an	 additional	 MOFA	 restricted	 to	 pulmonary	 carcinoid	 samples	 only	(MOFA	LNET;	Figure	4A;	Supplementary	Figure	17).	This	MOFA	 identified	 five	 latent	 factors	that	explained	at	least	2%	of	the	variance	in	one	dataset.	As	expected,	the	first	two	latent	factors	of	the	MOFA	LNET	were	highly	correlated	with	LF2	and	LF3	from	the	MOFA	LNEN,	respectively	(Pearson	 correlation	 greater	 than	0.96;	Supplementary	Figure	13B),	 and	 explained	41%	and	35%	 of	 the	 variance	 in	 methylation	 and	 expression,	 respectively.	 Integrative	 consensus	clustering	 using	 LF1	 and	 LF2	 of	 the	 MOFA	 LNET	 identified	 three	 clusters	 (Supplementary	
Figure	 18):	 cluster	 Carcinoid	 A1	 and	 cluster	 Carcinoid	 A2,	 that	 together	 correspond	 to	 the	samples	 in	 cluster	 Carcinoid	 A	 of	 the	 MOFA	 LNEN,	 plus	 the	 supra-carcinoids;	 and	 cluster	Carcinoid	B	(as	for	the	clustering	of	LNEN	samples,	a	clustering	based	on	LF1-LF5	weighted	by	their	proportion	of	variance	explained,	led	to	the	exact	same	clusters;	Supplementary	Figure	8).	LF2	was	associated	with	age,	with	cluster	Carcinoid	A1	enriched	for	older	patients	([60,	90)	years	old)	and	cluster	Carcinoid	A2	enriched	for	younger	patients	([15,	60)	years	old).	We	applied	GSEA	 to	 identify	 the	pathways	associated	with	 the	different	 latent	 factors.	We	found	 significant	 associations	 with	 the	 immune	 system	 and	 the	 retinoid	 and	 xenobiotic	metabolism	 pathways	 (Supplementary	 Table	 6).	 Numerous	 Gene	 Ontology	 (GO)	 terms	 and	KEGG	 pathways	 were	 related	 to	 the	 immune	 system,	 immune	 cell	 migration,	 and	 infectious	diseases.	The	GO	terms	and	KEGG	pathways	related	to	immune	cell	migration	included	leukocyte	migration,	chemotaxis,	cytokines,	and	interleukin	17	signalling.	In	particular,	the	expression	of	all	
β-chemokines	 (including	 CCL2,	 CCL7,	 CCL19,	 CCL21,	 CCL22,	 known	 to	 attract	 monocytes	 and	dendritic	cells)21	(Supplementary	Table	6),	and	all	CXC	chemokines	(such	as	IL8,	CXCL1,	CXCL3,	and	 CXCL5,	 known	 to	 attract	 neutrophils)22,	 were	 positively	 correlated	with	MOFA	 LNEN	 LF1	(separating	pulmonary	carcinoids	from	LCNEC)	and	negatively	correlated	with	MOFA	LNET	LF2	(separating	clusters	Carcinoid	A1	and	A2).	The	different	LNET	clusters	did	not	differ	in	their	total	amounts	of	estimated	proportions	of	immune	 cells,	 but	 they	 did	 differ	 in	 their	 composition	 (Supplementary	 Figure	 19):	 cluster	Carcinoid	A	(particularly	A1)	was	significantly	enriched	in	dendritic	cells,	and	cluster	Carcinoid	B,	in	monocytes	(Figure	4B,	upper	panel).	As	monocytes	can	differentiate	into	dendritic	cells	in	a	favourable	environment23,	we	assessed	the	levels	of	LAMP3	and	CD1A	dendritic-cells	markers24,	and	found	that	samples	in	cluster	Carcinoid	A1	presented	high	expression	levels	of	these	genes	(Figure	4B,	lower	panel),	implying	that	this	cluster	was	indeed	enriched	for	dendritic	cells.	We	pursued	this	further	by	assessing	the	CD1A	protein	levels	by	immunohistochemistry	(IHC)	in	an	independent	 series	of	pulmonary	 carcinoids,	 and	 found	 that	60%	of	 them	 (12	out	of	20)	were	enriched	 in	 CDA1-positive	 dendritic	 cells,	 confirming	 the	 presence	 of	 dendritic	 cells	 in	 a	subgroup	of	pulmonary	carcinoids	(Figure	4C;	Supplementary	Table	9).	Regarding	the	retinoid	and	xenobiotic	metabolism	pathways	(e.g.,	elimination	of	drugs	and	environmental	pollutants),	the	main	genes	driving	the	correlation	with	MOFA	latent	factors	were	the	 phase	 II	 enzymes	 involved	 in	 glucuronosyl-transferase	 activity	 (Supplementary	Table	6),	but	also	the	phase	I	cytochrome	P450	(CYP)	proteins.	These	pathways	were	positively	correlated	with	MOFA	LNEN	LF2	(separating	LNEN	clusters	A	and	B)	and	negatively	correlated	with	MOFA	
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LNET	LF1	(separating	LNET	clusters	A1	and	A2	from	cluster	B).	Indeed,	we	found	that	samples	in	cluster	 Carcinoid	 B	 were	 characterised	 by	 high	 levels	 of	 the	 CYP	 family	 of	 genes,	 and	 a	 very	strong	 expression	 of	 several	 UDP	 glucuronosyl-transferases	UGT	 genes	 (median	 FPKM=4.6	 in	
UGT2A3	 and	 28.1	 in	 UGT2B	 genes;	 Figure	 4D),	 which	 contrasts	 with	 the	 low	 levels	 in	 other	carcinoids	(median	FPKM=0	for	both	UGT2A3	and	UGT2B;	Figure	4D),	LCNEC	(median	FPKM=0	and	1.2	for	UGT2A3	and	UGT2B;	Supplementary	Figure	20)	and	SCLC	(median	FPKM=0	and	0.3	for	UGT2A3	and	UGT2B;	Supplementary	Figure	20).		
Molecular	groups	of	pulmonary	carcinoids	We	explored	the	molecular	characteristics	of	each	cluster	 from	the	MOFA	LNET	based	on	their	core	differentially	expressed	coding	genes	(core-DEGs,	genes	which	expression	 levels	defined	a	given	 group	 of	 samples),	 corresponding	 promoter	 methylation	 profiles	 (Figure	 5A;	
Supplementary	Table	10),	 and	 their	 somatic	mutational	patterns	 (Figure	3A;	Figure	4A).	To	achieve	this	goal,	we	computed	the	DEGs	in	all	pairwise	comparisons	between	a	focal	group	and	the	other	groups,	and	then	defined	core-DEGs	as	the	intersection	of	the	resulting	gene	sets.	We	show	in	Supplementary	Figure	21	 that	core-DEGs	are	almost	exclusively	a	subset	of	the	DEGs	between	 the	 focal	 group	 and	 samples	 from	all	 other	 groups	 taken	 together.	We	 correlated	 the	gene	 expression	 and	 promoter	 methylation	 data	 of	 the	 core-DEGs	 to	 identify	 genes,	 which	expression	could	be	mainly	explained	by	their	methylation	patterns	(Figure	5A).	One	of	the	top	correlations	 was	 found	 for	HNF1A	 and	HNF4A	homeobox	 genes	 (Supplementary	 Figure	 22),	which	were	 strongly	down-regulated	 in	 cluster	Carcinoid	A1	 samples	 (Supplementary	Figure	
23).	 In	addition,	 the	promoter	regions	of	 these	genes	also	harboured	core-DMPs	(Differentially	Methylated	Positions)	of	cluster	Carcinoid	A1,	indicating	that	their	methylation	profile	is	specific	of	this	cluster	(Supplementary	Table	11).	These	two	genes	have	been	reported	as	having	a	role	in	the	transcriptional	regulation	of	ANGPTL3,	CYP,	and	UGT	genes25,	and	could	thus	explain	the	differential	expression	of	these	genes	between	the	clusters.	Samples	in	cluster	Carcinoid	A1	were	also	characterised	by	high-expression	levels	of	the	delta	like	canonical	Notch	ligand	3	(DLL3,	75%	with	 FPKM>1)	 and	 its	 activator	 the	 achaete-scute	 family	 bHLH	 transcription	 factor	 1	 (ASCL1)	(Figure	5A;	Supplementary	Table	10),	similar	 to	SCLC	and	LCNEC	(Figure	5B);	however,	 the	expression	levels	of	NOTCH	genes	did	not	differ	between	the	different	groups	(Supplementary	
Figure	 24).	 The	 supra-carcinoids	 were	 negative	 for	 DLL3	 expression	 (Figure	 5B),	 and	 had	generally	 high	 expression	 levels	 of	 NOTCH1-3	 (Supplementary	 Figure	 24).	 We	 additionally	tested	 the	 DLL3	 protein	 levels	 in	 the	 aforementioned	 independent	 series	 of	 20	 pulmonary	carcinoids	and	found	40%	(eight	out	of	20)	with	relatively	high	expression	of	DLL3	(Figure	4D;	
Supplementary	Table	9),	while	in	the	other	12	samples	DLL3	was	strikingly	absent	(Figure	4D;	
Supplementary	Table	9).	 Furthermore,	we	 found	 a	 correlation	 between	 the	 protein	 levels	 of	DLL3	 and	 CD1A	 (Pearson	 test	 p-value=0.00034;	 Supplementary	 Figure	 25),	 providing	additional	 evidence	 for	 the	 existence	 of	 a	DLL3+	CD1A+	 subgroup	 of	 carcinoids.	 Core-DEGs	 in	cluster	 Carcinoid	 A2	 included	 the	 low	 levels	 of	 SLIT1	 (slit	 guidance	 ligand	 1;	 97%	 with	FPKM<0.01),	 and	ROBO1	(roundabout	 guidance	 receptor	1;	 56%	with	 FPKM<1)	 (Figure	5A-B;	
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Supplementary	Table	10).	This	cluster	also	contained	the	four	samples	with	somatic	mutations	in	 the	 eukaryotic	 translation	 initiation	 factor	 1A	 X-linked	 (EIF1AX)	 gene	 (Figure	 4A).	Concordantly,	samples	with	EIF1AX	mutations	had	significantly	higher	coordinates	on	the	MOFA	LNET	LF2	(t-test	p-value=0.0342).	As	expected	based	on	Figure	4D,	several	UGT	genes	were	core-DEGs	of	cluster	Carcinoid	B	(Figure	5A).	Also,	 accordingly	with	 the	worse	 survival	 of	 patients	 in	 this	 cluster	 (Figure	2A),	these	samples	were	also	characterised	by	the	expression	of	angiopoietin	 like	3	(ANGPTL3,	90%	with	FPKM>1),	and	the	erb-b2	receptor	 tyrosine	kinase	4	(ERBB4,	67%	with	FPKM>1)	(Figure	
5B).	 This	 cluster	 was	 also	 characterised	 by	 the	 universal	 downregulation	 of	 orthopedia	homeobox	(OTP;	90%	with	FPKM<1),	and	NK2	homeobox	1	(NKX2-1;	90%	FPKM<1)	(Figure	5B).	Interestingly,	 the	 SCLC-combined	 LCNEC	 sample	 (S00602)	 that	 clustered	 with	 the	 pulmonary	carcinoids	 in	 the	MOFA	LNEN	(Figure	1A)	was	 the	only	LCNEC	 in	our	 series	harbouring	high-expression	 levels	 of	 OTP	 (290.26	 FPKM	 vs	 9.89	 FPKM	 for	 the	 2nd	 highest	 within	 LCNEC,	 the	median	for	LCNEC	being	0.22	FPKM).	UGT	genes,	ANGPTL3,	and	ERBB4	were	also	core-DEGs	of	cluster	 B	 samples	when	 compared	 to	 LNEN	 clusters	 Carcinoid	 A	 and	 LCNEC	 (Supplementary	
Table	12),	 which	 indicates	 that	 their	 expression	 levels	 also	 significantly	 differed	 from	 that	 of	LCNEC.	Cluster	Carcinoid	B	included	all	observed	MEN1	mutations,	which	is	consistent	with	the	fact	 that	samples	with	MEN1	mutations	had	significantly	 lower	coordinates	on	the	MOFA	LNET	LF1	(t-test	p-value=7x10-6;	Figure	4A).	Nevertheless,	mutations	in	this	gene	did	not	explain	the	poorer	 prognosis	 of	 this	 group	 of	 samples	 compared	 to	 other	 LNET	 (logrank	 p-value>0.05;	
Supplementary	Figure	26).	To	gain	some	insights	into	what	might	be	driving	the	bad	prognosis	of	cluster	Carcinoid	B	samples,	we	performed	a	GSEA	of	mutations	 in	hallmarks	of	cancer	gene	sets	 19,20;	 while	 clusters	 Carcinoid	 A1	 and	 A2	 were	 not	 enriched	 for	 any	 hallmark	 of	 cancer,	cluster	Carcinoid	B	was	significantly	enriched	for	genes	involved	in	evading	growth	suppressor,	sustaining	proliferative	signalling,	and	genome	instability	and	mutation	at	 the	5%	FDR	(Figure	
5C).	We	also	performed	a	Cox	regression	with	elastic	net	regularisation	based	on	the	core-DEGs	of	this	cluster	();	the	model	selected	eight	coding	genes	explaining	the	overall	survival,	OTP	being	one	of	them	(Figure	5D;	Supplementary	Table	13).	Further	supporting	their	prognostic	value,	we	found	that	the	expression	of	four	of	these	genes	was	significantly	different	between	the	good	and	 the	poor-prognosis	 atypical	 carcinoids	based	on	 the	machine-learning	predictions	 (Figure	
1C,	upper	panel;	Supplementary	Figure	27).	Finally,	we	also	checked	the	MKI67	expression	levels	in	the	different	molecular	groups	and	found	relatively	low	levels	in	the	clusters	Carcinoids	A1,	A2,	and	B	(78%	with	FPKM<1)	and	high	levels	 in	 the	 supra-carcinoids	 (FPKM>1	 in	 the	 three	 samples).	As	expected,	LCNECs	and	SCLCs	carried	high	levels	of	this	gene	(FPKM>1	in	99	and	92%	of	the	samples,	respectively).	Although	the	levels	of	MKI67	 for	each	of	the	clusters	were	different,	 further	analyses	showed	that	MKI67	expression	 levels	 alone	 were	 not	 able	 to	 accurately	 separate	 good-	 from	 poor-prognosis	pulmonary	carcinoids	(Supplementary	Figure	11B-C).	An	 overview	 of	 the	 different	 molecular	 groups	 of	 pulmonary	 carcinoids	 and	 their	 most	relevant	characteristics	is	displayed	in	Figure	6.	
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Discussion	Lung	 neuroendocrine	 neoplasms	 are	 a	 heterogeneous	 group	 of	 tumours	with	 variable	 clinical	outcomes.	 Here,	 we	 characterised	 and	 contrasted	 their	 molecular	 profiles	 through	 integrative	analysis	of	transcriptome	and	methylome	data,	using	both	machine-learning	(ML)	techniques	and	multi-omics	 factor	 analyses	 (MOFA).	 ML	 analyses	 showed	 that	 the	 molecular	 profiles	 could	distinguish	 survival	 outcomes	 within	 patients	 with	 atypical	 carcinoid	 morphological	 features,	splitting	them	into	patients	with	good	typical	carcinoid-like	survival	and	patients	with	a	clinical	outcome	 similar	 to	 LCNEC.	 Overall,	 out	 of	 the	 35	 histopathological	 atypical	 carcinoids,	 ML	reclassified	12	into	the	typical	category.	Unsupervised	 MOFA	 and	 subsequent	 gene-set	 enrichment	 analyses	 unveiled	 the	 immune	system	and	the	retinoid	and	xenobiotic	metabolism	as	key	deregulated	processes	in	pulmonary	carcinoids,	 and	 identified	 three	molecular	groups—clusters—with	clinical	 implications	 (Figure	
6).	The	first	group	(cluster	A1)	presented	high	infiltration	by	dendritic	cells,	which	are	believed	to	promote	 the	 recruitment	 of	 immune	effector	 cells	 resulting	 in	 a	 strongly	 active	 immunity26.	Samples	in	cluster	A1	showed	overexpression	of	ASCL1	and	DLL3.	The	transcription	factor	ASCL1	is	a	master	regulator	that	induces	neuronal	and	neuroendocrine	differentiation.	It	regulates	the	expression	of	DLL3,	which	encodes	an	inhibitor	of	the	Notch	pathway27.	Overexpression	of	ASCL1	and	DLL3	 is	 a	 characteristic	 of	 the	 SCLC	 of	 the	 classic	 subtype27	 and	 the	 type-I	 LCNEC12.	 We	validated	the	expression	of	DLL3	in	an	independent	series	of	20	pulmonary	carcinoids	assessed	by	immunohistochemistry	(IHC;	40%	positive).	The	fact	that	we	found	a	correlation	between	the	protein	levels	of	DLL3	and	CD1A	(a	marker	of	dendritic	cells	also	assessed	by	IHC	in	this	series;	60%	positive)	 provides	 orthogonal	 evidence	 to	 support	 the	 existence	 of	 this	molecular	 group.	Phase	I	trials	have	provided	evidence	for	clinical	activity	of	the	anti-DLL3	humanized	monoclonal	antibody	in	high–DLL3-expressing	SCLCs	and	LCNECs28,	and	additional	clinical	trials	are	ongoing	in	other	cancer	types.	The	 second	 group	 (cluster	 A2)	 harboured	 recurrent	 somatic	 mutations	 in	 EIF1AX,	 and	showed	down-regulation	of	the	SLIT1	and	ROBO1	genes.	SLIT	and	ROBO	proteins	are	known	to	be	 axon-guidance	 molecules	 involved	 in	 the	 development	 of	 the	 nervous	 system29,	 but	 the	SLIT/ROBO	 signalling	 has	 also	 been	 associated	 with	 cancer	 development,	 progression	 and	metastasis.	Pulmonary	neuroendocrine	cells	(PNEC)	represent	1%	of	the	total	lung	epithelial	cell	population30,	they	reside	isolated	(Kultchinsky	cells)	or	in	clusters	named	neuroepithelial	bodies	(NEBs),	and	are	believed	to	be	the	cell	of	origin	of	most	lung	neuroendocrine	neoplasms31.	In	the	normal	lung,	it	has	been	shown	that	ROBO1/2	are	expressed,	exclusively,	in	the	PNECs,	and	that	the	SLIT/ROBO	signalling	is	required	for	PNEC	assembly	and	maintenance	in	NEBs32.	In	cancer,	this	 pathway	 mainly	 suppresses	 tumour	 progression	 by	 regulating	 invasion,	 migration,	 and	apoptosis,	and	therefore,	 is	often	down-regulated	in	many	cancer	types29.	More	specifically,	 the	SLIT1/ROBO1	 interaction	 can	 inhibit	 cell	 invasion	by	 inhibiting	 the	SDF1/CXCR4	axis,	 and	 can	attenuate	 cell	 cycle	 progression	 by	 destruction	 of	 β-catenin	 and	 CDC4229.	 Potential	 clinical	avenues	to	this	finding	exist,	especially	the	on-going	development	of	CXCR4	inhibitors.	
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The	third	molecular	group	(cluster	B)	was	enriched	in	monocytes	and	depleted	of	dendritic	cells,	and	had	the	worst	median	survival.	Even	in	the	presence	of	T	cell	infiltration,	this	immune	contexture	 suggests	 an	 inactive	 immune	 response,	 dominated	by	monocytes	 and	macrophages	with	 potent	 immunosuppressive	 functions,	 and	 almost	 devoid	 of	 the	 most	 potent	 antigen-presenting	cells,	dendritic	cells,	suggesting	dendritic	cell-based	immunotherapy	as	a	therapeutic	option	 for	 this	 group	 of	 samples33.	 Cluster	 B	 was	 also	 characterised	 by	 recurrent	 somatic	mutations	 in	MEN1,	 the	most	 frequently	 altered	 gene	 in	 pulmonary	 carcinoids	 and	 pancreatic	NETs34,	which	 is	 in	 line	with	 the	common	embryologic	origin	of	pancreas	and	 lung.	MEN1	was	inactivated	by	genomic	rearrangement	due	to	a	chromothripsis	event	affecting	chromosomes	11	and	 20	 in	 one	 of	 our	 samples.	 This	 observation,	 together	 with	 two	 additional	 reported	 cases	involving	chromosomes	2,	12,	and	1311,	and	chromosomes	2,	11,	and	2035,	respectively,	suggest	that	chromothripsis	 is	a	rare	but	recurrent	event	 in	pulmonary	carcinoids.	 Interestingly,	MEN1	mutations	did	not	have	 a	 clear	prognostic	 value	 in	our	 series.	Regarding	 the	 above-mentioned	deregulation	 of	 the	 retinoid	 and	 xenobiotic	 metabolism	 in	 pulmonary	 carcinoids,	 samples	 in	cluster	B	 presented	 high	 levels	 of	UGT	 and	CYP	 genes.	 In	 line	with	 previous	 studies15,36,	 these	samples	 also	 harboured	 low	 levels	 of	OTP,	which	 gene	 expression	 levels	were	 correlated	with	survival	 in	 the	ML	 predictions.	 High	 levels	 of	ANGPTL3	 and	ERBB4	 were	 also	 detected	 in	 this	group	of	samples,	representing	candidate	therapeutic	opportunities.	ANGPTL3	is	involved	in	new	blood	 vessel	 growth	 and	 stimulation	 of	 the	 MAPK	 pathway37.	 This	 protein	 has	 been	 found	aberrantly	 expressed	 in	 several	 types	 of	 human	 cancers37.	 Similarly,	 overexpression	 of	 the	epidermal	growth	factor	receptor	ERBB4,	which	induces	a	variety	of	cellular	responses,	including	mitogenesis	and	differentiation,	has	also	been	associated	with	several	cancer	types38,39.	For	many	years,	it	has	been	widely	accepted	that	the	lung	well-differentiated	NETs	(typical	and	atypical	carcinoids)	have	unique	clinico-histopathological	traits	with	no	apparent	causative	relationship	 or	 common	 genetic,	 epidemiologic,	 or	 clinical	 traits	 with	 the	 lung	 poorly-differentiated	 SCLC	 and	 LCNEC3.	 While	 molecular	 studies	 have	 sustained	 this	 belief	 for	pulmonary	 carcinoids	 versus	 SCLC11,13,14,	 the	 identification	 of	 a	 carcinoid-like	 group	 of	LCNECs10,12,	the	recent	observation	of	LCNEC	arising	within	a	background	of	pre-existing	atypical	carcinoid40,	 and	 a	 recent	 proof-of-concept	 study	 supporting	 the	 progression	 from	 pulmonary	carcinoids	to	LCNEC	and	SCLC9,	suggest	that	the	separation	between	pulmonary	carcinoids	and	LCNEC	might	be	more	 subtle	 than	 initially	 thought,	 at	 least	 for	 a	 subset	of	patients.	Our	 study	supports	 the	 suggested	molecular	 link	 between	 pulmonary	 carcinoids	 and	 LCNEC,	 as	we	 have	identified	 a	 subgroup	 of	 atypical	 carcinoids,	 named	 supra-carcinoids,	 with	 a	 clear	 carcinoid	morphological	 pattern	 but	 with	 molecular	 characteristics	 similar	 to	 LCNEC.	 In	 our	 series,	 the	proportion	of	 supra-carcinoids	was	 in	 the	order	of	5.5%	 (six	out	of	110	pulmonary	 carcinoids	with	available	expression/methylation	data);	however,	considering	the	intermediate	phenotypes	observed	in	the	MOFA	LNEN,	the	exact	proportion	would	need	to	be	confirmed	in	larger	series.	We	found	high	estimated	levels	of	neutrophil	infiltration	in	the	supra-carcinoids.	For	both	supra-carcinoids	 and	 LCNEC	 (but	 not	 SCLC),	 the	 pathways	 related	 to	 neutrophil	 chemotaxis	 and	degranulation,	were	also	altered.	Neutrophil	infiltration	may	act	as	immunosuppressive	cells,	for	
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example	 through	 PDL1	 expression41.	 Indeed,	 the	 supra-carcinoids	 also	 presented	 levels	 of	immune	checkpoint	receptors	and	ligands	(including	PDL1	and	CTLA4)	similar—or	higher—than	those	of	LCNEC	and	SCLC,	 as	well	 as	up-regulation	of	other	 immunosuppressive	genes	 such	as	HLA-G,	 and	 interferon	 gamma	 that	 is	 speculated	 to	 promote	 cancer	 immune-evasion	 in	immunosuppressive	 environments42,43.	 If	 confirmed,	 this	 would	 point	 to	 a	 therapeutic	opportunity	for	these	tumours	since	strategies	aiming	at	decreasing	migration	of	neutrophils	to	tumoral	 areas,	 or	 decreasing	 the	 amount	 of	 neutrophils	 have	 shown	 efficacy	 in	 preclinical	models44.	Similarly,	immune	checkpoint	inhibitors,	currently	being	tested	in	clinical	trials,	might	also	be	a	therapeutic	option	for	these	patients.		Overall,	 although	 preliminary,	 our	 data	 suggest	 that	 supra-carcinoids	 could	 be	 diagnosed	based	 on	 a	 combination	 of	 morphological	 features	 (carcinoid-like	 morphology,	 useful	 for	 the	differential	 diagnosis	 with	 LCNEC/SCLC)	 and	 the	 high	 expression	 of	 a	 panel	 of	 immune	checkpoint	(IC)	genes	(LCNEC/SCLC-like	molecular	features,	useful	for	the	differential	diagnosis	with	other	carcinoids);	the	levels	of	IC	genes,	such	as	PD-L1,	VISTA,	and	LAG3,	could	also	be	used	to	 drive	 the	 therapeutic	 decision	 for	 patients	 harbouring	 a	 tumour	 belonging	 to	 this	 subset	 of	very	 aggressive	 carcinoids.	 Nevertheless,	 due	 to	 the	 very	 low	 number	 of	 supra-carcinoids	identified	 so	 far	 (n=6),	 follow-up	studies	are	warranted	 to	 comprehensively	 characterize	 these	tumours	from	pathological	and	molecular	standpoints,	to	evaluate	the	immune	cell	distribution,	and	to	establish	 if	 the	diagnosis	of	 these	supra-carcinoids	can	be	undertaken	 in	small	biopsies.	Finally,	 the	current	classification	only	recognises	the	existence	of	grade-1	(typical)	and	grade-2	(atypical)	 well-differentiated	 lung	 NETs,	 while	 the	 grade-3	would	 only	 be	 associated	with	 the	poorly-differentiated	SCLC	and	LCNEC;	however,	in	the	pancreas,	stomach	and	colon,	the	group	of	well-differentiated	grade-3	NETs	are	well	known	and	broadly	recognised45.	Whether	these	supra-carcinoids	 constitute	 a	 separate	 entity	 that	 may	 be	 the	 equivalent	 in	 the	 lung	 of	 the	gastroenteropancreatic,	well-differentiated,	grade-3	NETs	will	require	further	research.	In	summary,	this	study	provides	comprehensive	insights	into	the	molecular	characteristics	of	pulmonary	carcinoids,	especially	of	 the	understudied	atypical	 carcinoids.	We	have	 identified	three	well-characterized	molecular	groups	of	pulmonary	carcinoids	with	different	prognoses	and	clinical	 implications.	Finally,	 the	 identification	of	 supra-carcinoids	 further	 supports	 the	already	suggested	 molecular	 link	 between	 pulmonary	 carcinoids	 and	 LCNEC	 that	 warrants	 further	investigation.		
Methods	
Clinical	data	Collected	 clinical	 data	 included	 age	 (in	 years),	 sex	 (male	 or	 female),	 smoking	 status	 (never	smoker,	 former	 smoker,	 passive	 smoker,	 and	 current	 smoker),	 UICC/AJCC	 stage,	 professional	exposure,	 and	 survival	 (calculated	 in	months	 from	 surgery	 to	 last	 day	 of	 follow	 up	 or	 death).	These	data	were	merged	with	that	from	Fernandez-Cuesta	et	al,	Nat	comm	(2013),	George	et	al,	Nat	Comm	(2017),	and	George	et	al,	Nature,	(2015)11,12,14.	In	order	to	improve	the	power	of	the	statistical	 analyses,	 we	 regrouped	 some	 levels	 of	 variables	 that	 had	 few	 samples.	 Age	 was	
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discretized	into	3	categories	((15,	40],	(40,	60],	and	(60,	90]	years),	IUCC	stages	were	regrouped	into	 four	 categories	 (I,	 II,	 III,	 IV),	 and	 smoking	 status	 was	 regrouped	 into	 2	 categories	 (non-smoker,	that	includes	never	smokers	and	passive	smokers,	and	smoker,	that	includes	current	and	former	 smokers).	 In	 addition,	 one	 patient	 (S02236)	 that	was	 originally	 classified	 as	male	was	switched	 to	 female	based	on	 its	 concordant	whole-exome,	 transcriptome,	and	methylome	data,	and	one	patient	 (LNEN028)	 for	whom	no	sex	 information	was	available	was	classified	as	male	based	on	its	methylation	data	(Supplementary	Figure	28;	see	details	of	the	methods	used	in	the	DNA	sequencing,	expression,	and	methylation	sections	of	the	methods),	because	we	had	no	other	data	 type	 for	 this	 sample.	 Note	 that	 two	 SCLC	 samples	 from	 George	 et	 al,	 Nature,	 (2015)14	displayed	 Y	 chromosome	 expression	 patterns	 discordant	 with	 their	 clinical	 data	 (S02249	 and	S02293;	 Supplementary	 Figure	 28B),	 but	 because	 we	 did	 not	 perform	 any	 analysis	 of	 SCLC	samples	 that	 used	 sex	 information,	 this	 did	 not	 have	 any	 impact	 on	 our	 analyses.	 See	
Supplementary	Table	1	for	the	clinical	data	associated	with	the	samples.	We	 assessed	 the	 associations	 between	 clinical	 variables—a	 batch	 variable	 (sample	provider),	 the	 main	 variable	 of	 interest	 (histopathological	 type),	 and	 important	 biological	covariables	(sex,	age,	smoking	status,	and	tumour	stage)—using	Fisher’s	exact	test,	adjusting	the	
p-values	for	multiple	testing.	Using	samples	from	all	histopathological	types	(typical	and	atypical	carcinoids,	 LCNEC,	 and	 SCLC),	we	 found	 that	 the	 sample	 provider	was	 significantly	 associated	with	 the	 histopathological	 type	 (Supplementary	Figure	29A).	 Indeed,	 the	 20	 carcinoids	 from	one	of	the	providers	(provider	1)	are	all	atypical	carcinoids.	Nevertheless,	because	there	are	also	7	 atypical	 carcinoids	 from	 a	 second	 provider	 and	 5	 from	 a	 third	 one,	 variables	 provider	 and	histopathological	type	are	not	completely	confounded	and	we	could	check	for	batch	effects	in	the	following	molecular	 analysis	 by	making	 sure	 that	 the	molecular	 profiles	 of	 atypical	 carcinoids	from	provider	1	overlap	with	that	from	the	two	other	providers.	The	histopathological	type	was	significantly	associated	with	all	other	variables	(Supplementary	Figure	29A,	B,	and	C).		
Pathological	review	Some	of	 the	samples	 included	 in	this	manuscript	had	already	undergone	a	Central	Pathological	Review	 in	 the	 context	 of	 other	 published	 studies,	 so	 we	 used	 the	 classifications	 from	 the	supplementary	 tables	 of	 the	 corresponding	 manuscripts4,11,12,14,15.	 For	 the	 new	 ones,	 an	 HE	(hematoxylin	 eosin)	 stain	 from	 a	 representative	 FFPE	 block	was	 collected	 for	 all	 tumours	 for	pathological	 review.	 All	 tumours	 were	 classified	 according	 to	 the	 2015	WHO	 classification	 by	three	independent	pathologists	(EB,	BAA,	and	SL).	An	H&E	stain	was	also	performed	in	order	to	assess	 the	 quality	 of	 the	 frozen	 material	 used	 for	 molecular	 analyses	 and	 to	 confirm	 that	 all	frozen	samples	contained	at	least	70%	of	tumour	cells.		
Immunohistochemistry	FFPE	tissue	sections	(3µm	thick)	from	twenty	atypical	and	typical	carcinoids	were	deparaffinized	and	 stained	 with	 the	 Ventana	 DLL3	 (SP347)	 assay,	 UltraView	 Universal	 DAB	 Detection	 Kit	(Ventana	Medical	Systems	and	Amplification	Kit	(Ventana	Medical	Systems	-	Roche)	on	Ventana	
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ULTRA	 autostainer	 (Ventana,	 Roche,	 Meylan,	 France),	 and	 with	 the	 CD1	 rabbit	 monoclonal	antibody	(cl	EP3622)	(Ventana).	The	positivity	of	DLL3	was	defined	by	the	percentage	of	tumor	cells	exhibiting	a	cytoplasmic	staining,	whatever	the	intensity.	The	positivity	of	CD1A	was	defined	by	 the	 percentage	 of	 the	 total	 surface	 of	 the	 tumour	 exhibiting	 a	 membrane	 staining	 with	 1	corresponding	to	less	than	1%,	2	to	a	percentage	between	1%	and	5%,	and	3	to	more	than	5%.	Results	are	presented	Supplementary	Table	9	and	representative	slides	are	displayed	in	Figure	
4C.		
Statistical	analyses	All	tests	involving	multiple	comparisons	were	adjusted	using	the	Benjamini-Hochberg	procedure	controlling	the	false	discovery	rate	46	using	the	p.adjust	R	function	(stats	package	version	3.4.4).	All	 tests	 were	 two-sided.	 Also,	 a	 summary	 of	 the	 statistics	 associated	 to	 survival	 analyses	 is	provided	in	Supplementary	Table	14.		
Survival	analysis	We	 performed	 survival	 analysis	 using	 Cox’s	 proportional	 hazard	 model;	 we	 assessed	 the	significance	of	the	hazard	ratio	between	the	reference	and	the	other	levels	using	Wald	tests,	and	assessed	the	global	significance	of	the	model	using	the	logrank	test	statistic	(R	package	survival	v.	2.41-3).	Kaplan-Meier	 and	 forest	plots	were	drawn	using	R	package	 survminer	 (v.	 0.4.2).	Note	that	 three	 LCNEC	 samples	 from	 George	 et	 al,	 Nature	 (2015)14	 had	 missing	 survival	 censor	information	and	were	thus	excluded	from	the	analysis	(samples	S01580,	S01581,	and	S01586).		
DNA	extraction	Samples	 included	 were	 extracted	 using	 the	 Gentra	 Puregene	 tissue	 kit	 4g	 (Qiagen,	 Hilden,	Germany),	 following	 manufacturer's	 instructions.	 All	 DNA	 samples	 were	 quantified	 by	 the	fluorometric	 method	 (Quant-iT	 PicoGreen	 dsDNA	 Assay,	 Life	 Technologies,	 CA,	 USA),	 and	assessed	 for	 purity	 by	 NanoDrop	 (Thermo	 Scientific,	 MA,	 USA)	 260/280	 and	 260/230	 ratio	measurements.	DNA	integrity	of	Fresh	Frozen	samples	was	checked	by	electrophoresis	in	a	1.3%	agarose	gel.		
RNA	extraction	Samples	 included	 were	 extracted	 using	 the	 Allprep	 DNA/RNA	 extraction	 kit	 (Qiagen,	 Hilden,	Germany),	following	manufacturer's	instructions.	All	RNA	samples	were	treated	with	DNAse	I	for	15min	at	30ºC.	RNA	integrity	of	frozen	samples	was	checked	with	Agilent	2100	Electrophoresis	Bioanalyser	 system	 (Agilent	 Biotechnologies,	 Santa	 Clara,	 CA95051,	 United	 States)	 using	 RNA	6000	Nano	Kit	(Agilent	Biotechnologies).		
DNA	Sequencing	
Whole-Genome	sequencing	(WGS)	
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Whole-genome	sequencing	was	performed	on	3	fresh	frozen	pulmonary	carcinoids	and	matched-blood	samples	by	the	Centre	National	de	Recherche	en	Génomique	Humaine	(CNRGH,	Institut	de	Biologie	François	Jacob,	CEA,	Evry,	France).	After	a	complete	quality	control,	genomic	DNA	(1µg)	has	been	used	to	prepare	a	library	for	whole	genome	sequencing,	using	the	Illumina	TruSeq	DNA	PCR-Free	 Library	 Preparation	 Kit	 (Illumina	 Inc.,	 CA,	 USA),	 according	 to	 the	 manufacturer's	instructions.	After	normalisation	and	quality	control,	qualified	libraries	have	been	sequenced	on	a	HiSeqX5	platform	from	Illumina	(Illumina	Inc.,	CA,	USA),	as	paired-end	150	bp	reads.	One	lane	of	HiSeqX5	flow	cell	has	been	produced	for	each	sample,	in	order	to	reach	an	average	sequencing	depth	of	30x	for	each	sample.	Sequence	quality	parameters	have	been	assessed	throughout	the	sequencing	 run	 and	 standard	 bioinformatics	 analysis	 of	 sequencing	 data	 was	 based	 on	 the	Illumina	pipeline	to	generate	fatsq	file	for	each	sample.		
Whole-Exome	sequencing	(WES)	Whole	exome	sequencing	was	performed	on	16	 fresh	 frozen	atypical	carcinoids	 in	 the	Cologne	Centre	 for	 Genomics.	 Exomes	 were	 prepared	 by	 fragmenting	 1	 μg	 of	 DNA	 using	 sonication	technology	 (Bioruptor,	Diagenode,	Liège,	Belgium)	 followed	by	end	repair	and	adapter	 ligation	including	 incorporation	 of	 Illumina	 TruSeq	 index	 barcodes	 on	 a	 Biomek	 FX	 laboratory	automation	 workstation	 from	 Beckman	 Coulter	 (Beckman	 Coulter,	 Brea,	 CA,	 USA).	 After	 size	selection	and	quantification,	pools	of	five	libraries	each	were	subjected	to	enrichment	using	the	SeqCap	EZ	v2	Library	kit	 from	NimbleGen	 (44Mb).	After	validation	 (2200	TapeStation;	Agilent	Technologies,	 CA,	 USA),	 the	 pools	 were	 quantified	 using	 the	 KAPA	 Library	 Quantification	 kit	(Peqlab,	Erlangen,	Germany)	and	the	7900HT	Sequence	Detection	System	(Applied	Biosystems,	Waltham,	 MA,	 USA),	 and	 subsequently	 sequenced	 on	 an	 Illumina	 HiSeq	 2000	 sequencing	instrument	 using	 a	 paired-end	 2	 ×	 100	 bp	 protocol	 and	 an	 allocation	 of	 one	 pool	 with	 5	exomes/lane.	The	expected	average	coverage	was	~120X	after	removal	of	duplicates	(11	GB).		
Targeted	sequencing	Targeted	 sequencing	 was	 performed	 on	 the	 same	 16	 fresh	 frozen	 atypical	 carcinoids	 and	 13	matched	normal	 tissue	 for	 the	 samples	with	 enough	DNA.	Three	 sets	of	primer	 covering	1331	amplicons	of	150-200	bp	were	designed	with	the	QIAGEN	GeneRead	DNAseq	custom	V2	Builder	tool	 on	 GRCh37	 (gencode	 version	 19).	 Target	 enrichment	was	 performed	 using	 the	 GeneRead	DNAseq	 Panel	 PCR	 Kit	 V2	 (QIAGEN)	 following	 a	 validated	 in-house	 protocol	 (IARC).	 The	multiplex	PCR	was	performed	with	6	separated	primers	pools	((1)1	pool	covering	786	amplicons,	(2)	4	pools	covering	498	amplicons,	and	(3)	1	pool	covering	47	amplicons).	Per	pool,	20ng	(1)	or	10ng	(2	and	3)	of	DNA	were	dispensed	and	air-dried	(only	2	and	3).	Subsequently	11µL	(1)	or	5µl	(2	and	3)	of	 the	PCR	mix	were	added	[containing	5.5µL	(1)	or	2.5µl	(2	and	3)	Primer	mix	pool	(2X),	2.2µL	(1)	or	1µl	(2	and	3)	PCR	Buffer	(5X),	0.73µL	(1)	or	0.34µl	(2	and	3)	HotStar	Taq	DNA	Polymerase	(6U/µl)	and	0.57µL	(1)	or	1.16µl	(2	and	3)	H2O]	and	the	DNA	were	amplified	in	a	96	well	plate	as	following:	15	min	at	95°C;	25	(1),	21	(2),	or	23	(3)	cycles	of	15	sec	at	95°C	and	4	min	
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at	 60°C;	 and	 10	min	 at	 72°C.	 For	 each	 sample,	 amplified	 PCR	 products	were	 pooled	 together,	purified	using	1.8X	 volume	of	 SeraPure	magnetic	 beads	 (prepared	 in-house	 following	protocol	developed	by	Faircloth	&	Glenn,	Ecol.	And	Evol.	Biology,	Univ.	of	California,	Los	Angeles)	(1)	or	NucleoMag®	NGS	Clean-up	 from	Macherey-Nagel	 (2	and	3)	and	quantified	by	Qubit	DNA	high-sensitivity	assay	kit	(Invitrogen	Corporation).	100ng	of	purified	PCR	product	(6µl)	were	used	for	the	 library	 preparation	with	 the	 NEBNext	 Fast	 DNA	 Library	 Prep	 Set	 (New	 England	 BioLabs)	following	 an	 in-house	 validated	 protocol	 (IARC).	 End-repair	was	 performed	 [1.5µl	 of	NEBNext	End	 Repair	 Reaction	 Buffer,	 0.75µL	 of	 NEBNext	 End	 Repair	 Enzyme	Mix,	 and	 6.75µL	 of	 H2O]	followed	 by	 ligation	 to	 specific	 adapters	 and	 in-house	 prepared	 individual	 barcodes	 (Eurofins	MWG	Operon,	Germany)	[4.35µl	of	H2O,	2.5µl	of	T4	DNA	Ligase	Buffer	for	Ion	Torrent,	0.7µl	of	Ion	P1	adaptor	(double-stranded),	0.25µl	of	Bst	2.0	WarmStart	DNA	Polymerase,	1.5µl	of	T4	DNA	ligase,	and	0.7µl	of	 in-house	barcodes].	Bead	purification	of	1.8X	was	applied	 to	clean	 libraries	and	 100	 ng	 of	 adaptator	 ligated	 DNA	 were	 amplified	 with	 15µl	 of	 Master	 Mix	 Amplification	[containing	1µl	of	Primers,	12.5µl	of	NEBNext	High-Fidelity	2X	PCR	Master	Mix,	and	1.5µl	of	H2O].	Pooling	 of	 libraries	 was	 performed	 equimolarly	 and	 loaded	 on	 a	 2%	 agarose	 gel	 for	electrophoresis	 (220V,	 40	 minutes).	 Using	 the	 GeneClean™	 Turbo	 kit	 (MP	 Biomedicals,	 USA)	pooled	DNA	libraries	were	recovered	from	selected	fragments	of	200-300	bp	in	length.	Libraries	quality	and	quantity	were	assessed	using	Agilent	High	Sensitivity	DNA	kit	on	 the	Agilent	2100	Bioanalyzer	 on-chip	 electrophoreses	 (Agilent	 Technologies).	 Sequencing	 of	 the	 libraries	 was	performed	 on	 the	 Ion	 TorrentTM	 Proton	 Sequencer	 (Life	 Technologies	 Corp)	 aiming	 for	 deep	coverage	(>	250X),	using	the	Ion	PITM	Hi-QTTM	OT2	200	Kit	and	the	Ion	PITM	Hi-QTM	Sequencing	200	Kit	with	the	Ion	PITM	Chip	Kit	v3	following	the	manufacture’s	protocols.		
Data	processing	WGS	 and	 WES	 reads	 mapping	 on	 reference	 genome	 GRCh37	 (gencode	 version	 19)	 were	performed	using	our	in-house	workflow	(https://github.com/IARCbioinfo/alignment-nf,	revision	number	9092214665).	This	workflow	 is	based	on	 the	nextflow	domain-specific	 language47	and	consists	 in	 3	 steps:	 reads	 mapping	 (software	 bwa	 version	 0.7.12-r1044)48,	 duplicate	 marking	(software	samblaster,	version	0.1.22)49,	and	reads	sorting	(software	sambamba,	version	0.5.9)50.	Reads	mapping	for	the	targeted	sequencing	data	was	performed	using	the	Torrent	Suite	software	version	4.4.2	on	reference	genome	hg19.	Local	 realignment	around	 indels	was	 then	performed	for	both	using	software	ABRA	(version	0.97bLE)51	on	the	regions	from	the	bed	files	provided	by	Agilent	 (SeqCap_EZ_Exome_v2_probe-covered.bed)	 and	 QIAGEN,	 respectively,	 for	 the	WES	 and	targeted	 sequencing	data.	Consistency	between	 sex	 reported	 in	 the	 clinical	data	and	WES	data	was	assessed	by	computing	the	total	coverage	on	X	and	Y	chromosomes	(Supplementary	Figure	
28A).		
Variant	calling	and	filtering	WES	data.	We	re-performed	variant	calling	for	all	 typical	and	atypical	carcinoid	WES,	 including	already	published	data,	in	order	to	remove	the	possible	cofounding	effect	of	variant	calling	in	the	
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subsequent	 molecular	 characterization	 of	 carcinoids.	 Software	 Needlestack	 v1.1	(https://github.com/IARCbioinfo/needlestack)52	 was	 used	 to	 call	 variants.	 Needlestack	 is	 an	ultra-sensitive	multi-sample	variant	caller	that	uses	the	joint	information	from	multiple	samples	to	disentangle	 true	variants	 from	sequencing	errors.	We	performed	 two	separate	multi-sample	variant	 callings	 to	 avoid	 technical	 batch	 effects:	 (1)	 The	 16	 WES	 atypical	 carcinoids	 newly	sequenced	 in	 this	 study	 were	 analyzed	 together	 with	 64	 additional	 WES	 samples	 sequenced	using	the	same	protocol	from	another	study	in	order	to	increase	the	accuracy	of	Needlestack	to	estimate	the	sequencing	error	rate;	(2)	The	15	WES	LNET	(10	typical	and	5	atypical	carcinoids)	previously	 analyzed(Fernandez-Cuesta	 et	 al,	 Nat	 Comm	 2013)11	 were	 reanalyzed	 with	 their	matched-normal.	For	both	variant	callings,	we	used	default	software	parameters	except	 for	 the	minimum	median	coverage	to	consider	a	site	for	calling,	the	minimum	mapping	quality,	and	the	SNV	 and	 INDEL	 strand	 bias13	 threshold	 (they	 were	 set	 to	 20,	 13,	 4,	 and	 10	 respectively).	Annotation	 of	 resulting	 variant	 calling	 format	 (VCF)	 files	was	 then	 performed	with	 ANNOVAR	(2018Aprl16)53	 using	 the	 PopFreqAll	 (maximum	 frequency	 over	 all	 populations	 in	 ESP6500,	1000G,	 and	 ExAC	 germline	 databases),	 COSMIC	 v84,	 MCAP,	 REVEL,	 SIFT,	 and	 Polyphen	(dbnsfp30a)	databases.	We	 performed	 the	 same	 variant	 filtering	 after	 each	 of	 the	 two	 variant	 callings,	 based	 on	several	 stringent	 criteria.	 First,	 we	 only	 retained	 variants	 that	 have	 never	 been	 observed	 in	germline	databases	or	present	at	low	frequency	(≤0.001)	but	already	reported	as	somatic	in	the	COSMIC	database.	Second,	we	only	retained	variants	that	were	in	coding	regions	and	that	had	an	impact	 on	 expressed	 proteins:	 we	 filtered	 out	 silent,	 non-damaging	 single	 nucleotide	 variants	(based	on	MCAP,	REVEL,	SIFT	or	Polyphen2	databases)	and	variants	present	 in	non-expressed	genes	(mean	and	median	FPKM	<0.1	over	all	carcinoid	tumors).	Additionally,	for	calling	(2),	we	re-assessed	 the	 somatic	 status	 of	 variants	 reported	 by	 Needlestack	 in	 light	 of	 possible	contamination	 errors.	 Indeed,	Needlestack	 is	 a	 very	 sensitive	 caller	 and	will	 sometimes	 detect	low	 allelic	 fraction	 variants	 in	 normal	 tissue	 that	 actually	 come	 from	 contamination	 by	 tumor	cells.	In	such	cases	the	variant	is	found	in	both	matched	samples	and	is	reported	as	germline	but	we	still	considered	a	variant	as	somatic	if	its	allelic	fraction	in	the	normal	tissue	was	at	least	five	times	lower	than	the	allelic	fraction	observed	in	the	tumor.		Targeted	 sequencing	 data.	 Software	 Needlestack	 was	 also	 used	 to	 call	 variants	 on	 targeted	sequencing	data	from	16	atypical	carcinoids	and	their	matched	normal	tissue.	We	performed	the	calling	 with	 default	 parameters	 except	 for	 the	 phred-scaled	 q-value	 and	 minimum	 median	coverage	 to	 consider	 a	 site	 (20	 and	 10	 respectively).	 These	 parameters	 were	 decreased	compared	 to	WES	variants	 calling	because	we	wanted	 a	 larger	 sensitivity	 in	 the	 validation	 set	than	 in	 the	 discovery	 set.	 The	 annotation	 procedure	was	 the	 same	 as	 for	WES	 data.	 No	 other	filters	were	used.		Validation.	For	both	previously	published	data	and	data	generated	 in	this	study	we	only	report	somatic	 mutations	 that	 were	 validated	 using	 a	 different	 technique:	 targeted	 sequencing,	 RNA	
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sequencing	 (see	 below	 for	 variant	 calling	 in	 RNA-seq	 data),	 or	 Sanger	 sequencing.	 Results	 are	presented	Supplementary	Table	4.		
Structural	variant	calling	Somatic	copy	number	variations	(CNVs)	were	called	 from	WGS	data	using	an	 in-house	pipeline	(software	WGinR,	available	at	https://github.com/aviari/wginr)	that	consists	in	three	main	steps.	First,	 the	dependency	between	GC	 content	 and	 raw	read	 count	 is	modeled	using	a	 generalized	additive	 smoothing	model	with	 two	nested	windows	 in	order	 to	 catch	 short	 and	 long	distance	dependencies.	The	model	is	computed	on	a	subset	of	human	genome	mappable	regions	defined	by	 a	 narrow	 band	 around	 the	 mode	 of	 binned	 raw	 counts	 distribution.	 This	 limits	 the	incorporation	 of	 true	 biological	 signal	 (losses	 and	 gains)	 by	 selecting	 only	 regions	 with	(supposedly)	the	same	ploidy.		In	a	second	step,	we	collect	heterozygous	positions	in	the	matched	normal	sample	and	GC-corrected	read	counts	(RC)	and	alleles	frequencies	(AF)	at	these	positions	are	used	to	estimate	the	mean	tumour	ploidy	and	its	contamination	by	normal	tissue.	This	ploidy	model	is	then	used	to	infer	the	theoretical	absolute	copy	number	levels	in	the	tumour	sample.	In	the	 third	 step,	 a	 simultaneous	 segmentation	 of	 RC	 and	 AF	 signals	 (computed	 on	 all	mappable	regions)	 is	 performed	 using	 a	 bivariate	 Hidden	 Markov	 Model	 to	 generate	 an	 absolute	 copy	number	and	a	genotype	estimate	for	each	segment.	Somatic	structural	variants	(SV)	were	identified	using	an	in-house	tool	(crisscross,	available	at	 https://github.com/anso-sertier/crisscross)	 that	 uses	 WGS	 data	 and	 two	 complementary	signals	 from	 the	 read	 alignments:	 (a)	 discordant	 pair	 mapping	 (wrong	 read	 orientation	 or	incorrect	 insert-size)	 and	 (b)	 soft-clipping	 (unmapped	 first	 or	 last	 bases	 of	 reads)	 that	 allows	resolving	SV	breakpoints	at	the	base	pair	resolution.	A	cluster	of	discordant	pairs	and	one	or	two	clusters	of	soft-clipped	reads	defined	an	SV	candidate:	 the	discordant	pairs	cluster	defined	two	associated	 regions,	 possibly	 on	 different	 chromosomes	 and	 the	 soft-clipped	 reads	 cluster(s),	located	 in	 these	 regions,	pinpointed	 the	potential	 SV	breakpoint	positions.	We	 further	 checked	that	the	soft-clipped	bases	at	each	SV	breakpoint	were	correctly	aligned	in	the	neighbourhood	of	the	associated	region.	SV	events	were	then	classified	as	germline	or	somatic	depending	on	their	presence	in	the	matched	normal	sample.	Results	are	presented	Supplementary	Table	8	and	one	sample	is	highlighted	in	Figure	3C.	
	
Gene-set	enrichment	analysis	Gene-set	enrichment	for	somatic	mutations	was	assessed	independently	for	each	set	of	Hallmark	of	cancer	genes19	using	a	two-sided	Fisher’s	exact	test,	and	followed	by	a	correction	for	multiple	testing46.	We	built	the	contingency	tables	used	as	input	of	the	test	taking	into	account	genes	with	multiple	 mutations	 and	 used	 the	 fisher.test	 R	 function	 (stats	 package	 version	 3.4.4).	 We	 also	included	validated	mutations	(we	removed	silent	and	intron/exon	mutations)	reported	in	SCLC	13.	 In	 each	 group	 the	 p-values	 given	 by	 Fisher’s	 exact	 test	 performed	 for	 all	 Hallmarks	 were	adjusted	 for	multiple	 testing.	Supplementary	Table	5	 lists	 the	altered	hallmarks	 including	the	
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mutated	genes	and	the	associated	q-value	for	each	group,	as	well	as	the	mutated	genes	for	each	hallmarks	present	in	each	supra-carcinoid,	cluster	LNET,	LCNEC	and	SCLC	samples.	We	performed	several	robustness	analyses	to	assess	the	validity	of	our	results,	in	particular	with	regards	to	outlier	samples/genes	that	would	have	a	high	leverage	on	the	statistical	results,	i.e.,	 that	 would	 alone	 drive	 the	 significance	 of	 a	 particular	 hallmark.	 First,	 we	 assessed	 the	leverage	 of	 each	 individual	 sample	 using	 a	 jackknife	 procedure	 (i.e.,	 for	 each	 sample,	 we	performed	 the	GSE	 test	 after	 removing	 this	 sample).	 Second,	we	assessed	 the	 leverage	of	 each	gene	using	 a	 jackknife	 procedure	 (i.e.,	 for	 each	 gene,	 we	 performed	 the	 GSE	 test	 without	 this	gene).	 We	 observed	 that	 when	 we	 removed	 sample	 LNEN010	 from	 the	 cluster	 LNET	 B,	 the	sustaining	proliferative	signalling	hallmark	enrichment	became	non-significant	at	the	0.05	false	discovery	 rate	 threshold,	 but	 was	 still	 significant	 at	 the	 10%	 threshold	 (q-value=0.075;	Supplementary	Table	3).	Similarly,	we	observed	that	for	several	SCLC	samples,	once	the	sample	was	removed,	the	deregulating	cellular	energetics	and	inducing	angiogenesis	hallmarks	became	significant	 at	 the	 0.05	 false	 discovery	 rate	 threshold	 (Supplementary	 Table	 5).	 For	 supra-carcinoids	samples,	we	performed	GSE	for	each	sample	individually.	The	code	used	for	the	gene	set	enrichment	analyses	on	somatic	mutations	(Hallmarks_of_cancer_GSEA.R)	is	available	in	the	
Supplementary	 Software	 file	 1	 and	 the	 associated	 results	 are	 reported	 in	 Supplementary	
Table	5.		
RNA	Sequencing	
RNA-seq	data	RNA	sequencing	was	performed	on	20	fresh	frozen	atypical	carcinoids	in	the	Cologne	Center	for	Genomics.	Libraries	were	prepared	using	 the	 Illumina®	TruSeq®	RNA	sample	preparation	Kit.	Library	 preparation	 started	 with	 1µg	 total	 RNA.	 After	 poly-A	 selection	 (using	 poly-T	 oligo-attached	 magnetic	 beads),	 mRNA	 was	 purified	 and	 fragmented	 using	 divalent	 cations	 under	elevated	 temperature.	 The	 RNA	 fragments	 underwent	 reverse	 transcription	 using	 random	primers.	This	is	followed	by	second	strand	cDNA	synthesis	with	DNA	Polymerase	I	and	RNase	H.	After	end	repair	and	A-tailing,	 indexing	adapters	were	ligated.	The	products	were	then	purified	and	 amplified	 (14	 PCR	 cycles)	 to	 create	 the	 final	 cDNA	 libraries.	 After	 library	 validation	 and	quantification	(Agilent	2100	Bioanalyzer),	equimolar	amounts	of	 library	were	pooled.	The	pool	was	quantified	by	using	the	Peqlab	KAPA	Library	Quantification	Kit	and	the	Applied	Biosystems	7900HT	Sequence	Detection	 System.	The	pool	was	 sequenced	by	using	 an	 Illumina	TruSeq	PE	Cluster	Kit	v3	and	an	Illumina	TruSeq	SBS	Kit	v3-HS	on	an	Illumina	HiSeq	2000	sequencer	with	a	paired-end	(101x7x101	cycles)	protocol.		
Data	processing	The	210	raw	reads	files	(89	carcinoids,	69	LCNEC,	52	SCLC)	were	processed	in	3	steps	using	the	RNA-seq	 processing	 workflow	 based	 on	 the	 nextflow	 language47	 and	 accessible	 at	https://github.com/IARCbioinfo/RNAseq-nf	(revision	da7240d).	Reads	were	scanned	for	a	part	of	 Illumina’s	13bp	adapter	sequence	 ’AGATCGGAAGAGC’	at	 the	3’	end	using	Trim	Galore	v0.4.2	
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(Krueger	 2015)	 with	 default	 parameters.	 Reads	 were	 mapped	 to	 reference	 genome	 GRCh37	(gencode	version	19)	using	software	STAR	(v2.5.2b)54	with	recommended	parameters55.	(iii)	For	each	 sample,	 a	 raw	 read	 count	 table	 with	 gene-level	 quantification	 for	 each	 gene	 of	 the	comprehensive	 gencode	 gene	 annotation	 file	 (release	 19,	 containing	 57,822	 genes)	 was	generated	using	script	htseq-count	from	software	htseq	(v0.8.0)56.	Gene	fragments	per	kilobase	million	(FPKM)	of	all	genes	from	the	gencode	gene	annotation	file	were	computed	using	software	StringTie	(v1.3.3b)57	in	single	pass	mode	(no	new	transcript	discovery),	using	the	protocols	from	Pertea	et	al.	(2016)57	(nextflow	pipeline	accessible	at	https://github.com/IARCbioinfo/RNAseq-transcript-nf;	revision	c5d114e42d).	Quality	 control	 of	 the	 samples	 was	 performed	 at	 each	 step.	 Software	 FastQC	 (v.	 0.11.5;	https://www.bioinformatics.babraham.ac.uk/projects/fastqc/)	 was	 used	 to	 check	 raw	 reads	quality,	software	RSeQC	(v.	2.6.4)	was	used	to	check	alignment	quality	(number	of	mapped	reads,	proportion	of	uniquely	mapped	reads).	Software	MultiQC	(v.	0.9)58	was	used	to	aggregate	the	QC	results	 across	 samples.	 Concordance	 between	 sex	 reported	 in	 the	 clinical	 data	 and	 sex	chromosome	 gene	 expression	 patterns	 was	 performed	 by	 comparing	 the	 sum	 of	 variance-stabilized	 read	 counts	 (vst	 function	 from	 R	 package	 DESeq2)	 of	 each	 sample	 on	 the	 X	 and	 Y	chromosomes	(Supplementary	Figure	28B).		
Variant	calling	Software	 Needlestack	was	 also	 used	 to	 call	 variants	 on	 the	 20	 RNA	 sequencing	 data	 for	WES	variant	validation.	Default	parameters	were	used,	except	for	the	phred-scaled	q-value,	minimum	median	coverage	to	consider	a	site,	and	minimum	mapping	quality	(20,	10,	and	13	respectively).	The	annotation	procedure	was	the	same	as	for	WES	data.		
Fusion	transcript	analysis	RNA-seq	data	was	processed	as	previously	described11,13	to	detect	chimeric	transcripts.	In	brief,	paired-end	RNA-seq	reads	were	mapped	to	the	human	reference	genome	(NCBI37/hg19)	using	GSNAP.	 Potential	 chimeric	 fusion	 transcripts	 were	 identified	 using	 software	 TRUP59	 by	discordant	 read	pairs	and	by	 individual	 reads	mapping	 to	distinct	 chromosomal	 locations.	The	sequence	context	of	rearranged	transcripts	was	reconstructed	around	the	identified	breakpoint	and	 the	 assembled	 fusion	 transcript	 was	 then	 aligned	 to	 the	 human	 reference	 genome	 to	determine	 the	 genes	 involved	 in	 the	 fusion.	All	 interesting	 fusion-transcript	were	 validated	by	Sanger	 sequencing.	 The	 code	 used	 for	 the	 fusion	 transcript	 detection	 is	 available	 on	https://github.com/ruping/TRUP.	 All	 the	 associated	 results	 are	 presented	 Supplementary	
Table	7,	and	selected	genes	are	highlighted	in	Figure	3B.		
Unsupervised	analysis	of	expression	data	The	raw	read	counts	of	57,822	genes	from	the	210	samples	were	normalized	using	the	variance	stabilization	 transform	 (vst	 function	 from	 R	 package	 DESeq2	 v1.14.1)60;	 this	 transformation	
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enables	 comparisons	 between	 samples	 with	 different	 library	 sizes	 and	 different	 variances	 in	expression	across	genes.	We	removed	genes	 from	the	sex	chromosomes	 in	order	 to	reduce	the	influence	of	sex	on	the	expression	profiles,	resulting	in	a	matrix	of	gene	expression	with	54,851	genes	 and	 210	 samples.	We	 performed	 four	 analyses,	with	 different	 subsets	 of	 samples.	 i)	 An	analysis	with	 all	 210	 samples	 (LNEN	 and	 SCLC),	 ii)	 an	 analysis	with	 LNEN	 samples	 only	 (158	samples),	 iii)	an	analysis	with	LNET	and	SCLC	samples	only	(139	samples),	and	 iv)	an	analysis	with	LNET	samples	only	(89	samples).	For	each	analysis,	the	most	variable	genes	(explaining	50%	of	 the	 total	 variance	 in	 variance-stabilized	 read	 counts)	were	 selected	 (6398,	 6009,	 6234,	 and	5490	 genes,	 respectively,	 for	 i,	 ii,	 iii,	 and	 iv).	 Principal	 Component	 Analysis	 (PCA)	 was	 then	performed	 independently	 for	 each	 analysis	 (function	 dudi.pca	 from	 R	 package	 ade4	v1.7-8)61.	Results	are	presented	in	Supplementary	Figure	6;	see	the	Multi-omic	integration	section	of	the	methods	for	a	comparison	of	the	results	of	the	unsupervised	analysis	of	expression	data	with	that	of	the	other	omics.	We	 used	 the	 results	 from	 the	 PCA	 to	 detect	 outliers	 and	 batch	 effects	 in	 the	 expression	dataset.	We	did	not	detect	any	outliers	in	any	of	the	analyses	from	Supplementary	Figure	6.	We	further	studied	the	association	between	expression	data,	batch	(sample	provider),	and	5	clinical	variables	 of	 interest	 (histopathological	 type,	 age,	 sex,	 smoking	 status,	 and	 stage)	 using	 a	 PCA	regression	analysis.	For	each	principal	component,	we	fitted	separate	linear	models	with	each	of	the	6	covariables	of	interest	(provider	plus	the	5	clinical	variables)	and	adjusted	the	resulting	p-values	 for	multiple	 testing.	 Results	 highlighted	 an	 association	 between	 principal	 component	 2	and	provider,	histopathological	type,	and	sex,	and	an	association	between	principal	components	4	and	5	and	stage	(Supplementary	Figure	30A).	The	fact	that	both	histopathology	and	sample	provider	are	 jointly	significantly	associated	with	PC2	is	expected	given	their	non-independence	(Supplementary	 Figure	 29A	 and	 B).	 In	 order	 to	 assess	 whether	 there	 was	 a	 batch	 effect	explaining	the	variation	on	PC2,	we	investigated	the	range	of	samples	from	each	provider	on	PC2	(Supplementary	Figure	30B).	We	can	see	that	samples	from	Provider	1	and	provider	2	span	a	similar	 range	 on	 PC2	 (from	 values	 lower	 than-20	 to	 values	 greater	 than	 40).	 Restricting	 the	analysis	to	atypical	carcinoids,	we	can	further	see	that	AC	samples	from	provider	2	have	a	range	included	 in	 that	 of	 provider	 1,	 which	 is	 expected	 given	 their	 differing	 sample	 sizes	 (5	 from	provider	 2	 compared	 to	 20	 from	 provider	 1).	 Overall,	 this	 shows	 that	 samples	 from	 the	 two	providers	have	similar	profiles	and	can	be	combined.	In	addition,	we	found	that	the	samples	that	were	 independently	sequenced	 in	a	previous	study11	and	 in	 this	study	(samples	S00716_A	and	S00716_B,	 respectively)	 were	 spatially	 close	 in	 the	 PCA	 (technical	 replicates	 highlighted	 in	
Supplementary	Figure	30B).		
Supervised	analysis	of	expression	data	We	 performed	 three	 distinct	 differential	 expression	 (DE)	 analyzes.	 i)	 A	 comparison	 between	histopathological	types;	ii)	A	comparison	between	pulmonary	carcinoid	(LNET)	clusters	A1,	A2,	and	B	(see	Figure	5A	and	the	Multi-omic	integration	method	section);	iii)	a	comparison	between	
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lung	neuro-endocrine	neoplasm	 (LNEN)	 clusters	Carcinoid	A,	 Carcinoid	B,	 and	LCNEC	 (see	 the	Multi-omic	integration	method	section).	For	each	differential	expression	(DE)	analysis,	among	the	57,822	genes	 from	the	raw	read	count	tables,	genes	that	were	expressed	in	less	than	2	samples	were	removed	from	the	analysis,	using	a	threshold	of	1	fragment	per	million	reads	aligned.	We	also	removed	samples	with	missing	data	in	the	variables	of	interest	(either	histopathological	types,	LNET	clusters,	or	LNEN	clusters)	or	in	any	of	the	clinical	covariables	included	in	the	statistical	model	(sex	and	age).	This	resulted	in	 excluding	 two	 samples	 with	 missing	 age	 data	 from	 the	 three	 analyzes	 (samples	 S01093,	S02236),	and	further	excluding	three	samples	with	no	clear	histopathological	type	(classified	as	carcinoids	in	Supplementary	Table	1)	from	analysis	(i)	(samples	S00076,	S02126,	S02154).	For	each	analysis,	we	then	identified	DE	genes	from	the	raw	read	counts	using	R	package	DESeq2	(v.	1.21.5)60.	For	each	analysis,	we	fitted	a	model	with	the	variable	of	interest	(type,	LNET	cluster,	or	LNEN	cluster)	and	using	sex	(2	levels:	male	and	female),	and	age	(3	levels:	(16,	40],	(40,	60],	(60,	90])	as	covariables.	We	then	extracted	DE	genes	between	each	pair	of	groups,	and	adjusted	the	p-values	for	multiple	testing.	In	order	to	select	the	genes	that	have	the	largest	biological	effect,	we	tested	 the	null	hypothesis	 that	 the	 two	 focal	groups	had	 less	 than	2	absolute	 log2-fold	changes	differences.	For	each	analysis,	we	define	the	core	genes	of	a	focal	group	as	the	set	of	genes	that	are	DE	in	all	pairwise	comparisons	between	the	focal	group	and	other	groups;	they	correspond	to	genes	which	expression	level	is	specific	to	the	focal	group.	For	example,	given	three	groups—A,	B,	and	C—to	find	core	genes	which	expression	levels	uniquely	define	A	compared	to	both	B	and	C,	we	select	DE	genes	that	differentiate	A	from	B	(A	vs	B),	DE	genes	that	differentiate	A	from	C	(A	vs	C)	 and	 take	 the	 intersection	of	 these	gene	 sets	 [(A	vs	B)∩(A	vs	C)].	 	The	 code	used	 for	 the	DE	analyses	 (RNAseq_supervised.R)	 is	 available	 at	https://github.com/IARCbioinfo/RNAseq_analysis_scripts.	Results	of	analysis	(i)	are	reported	in	
Supplementary	Table	15	and	Supplementary	Figure	31;	results	of	analysis	(ii)	are	reported	in	
Supplementary	 Table	 10	 and	 Figure	 5A;	 results	 of	 analysis	 (iii)	 are	 reported	 in	
Supplementary	 Table	 12.	 See	 section	 Multi-omics	 integration	 for	 comparisons	 between	 the	analyses	based	on	histopathological	types	(analysis	(i))	from	all	‘omics	perspectives.	Note	that	an	alternative	method	for	finding	DE	genes	would	be	to	compare	a	focal	group	to	all	 the	 other	 samples	 together.	 For	 example,	 comparing	 group	 A	 to	 both	 groups	 B	 and	 C	simultaneously	[denoted	A	vs	(B	and	C)	or	A	vs	the	rest].	Note	that	this	would	find	genes	that	are	DE	between	A	and	the	average	level	of	expression	of	B	and	C,	and	thus	this	alternative	method	would	have	the	unwanted	behavior	of	including	the	genes	that	are	strongly	DE	in	the	comparison	of	A	vs	B,	but	with	similar	expression	levels	in	A	and	C.	In	order	to	compare	the	methods	we	used	to	detect	core	genes	with	this	alternative	method,	we	performed	an	analysis	similar	to	analysis	(ii)	but	 comparing	 a	 focal	 group	 to	 all	 the	 other	 samples	 simultaneously	 [A	 vs	 the	 rest].	 The	comparison	between	our	method	and	the	alternative	one	is	presented	in	Supplementary	Figure	
21	and	shows	that	our	analysis	provides	conservative	results	compared	to	testing	the	focal	group	
vs	 the	 rest.	 Indeed,	 core	DE	genes	 reported	are	almost	 exclusively	a	 subset	of	 the	genes	 found	when	comparing	the	focal	group	vs	the	rest.	
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Immune	contexture	deconvolution	from	expression	data	We	quantified	the	proportion	of	cells	that	belong	to	each	of	10	immune	cell	types	(B	cells,	M1,	M2,	monocytes,	 neutrophils,	 NK	 cells,	 CD4+	 T	 cells,	 CD8+	 T	 cells,	 CD4+	 regulatory	 T	 cells,	 and	dendritic	cells)	from	the	RNA-seq	data	using	software	quanTIseq	(downloaded	March	23	2018)62.	
quanTIseq	uses	a	rigorous	RNA-seq	processing	pipeline	to	quantify	the	gene	expression	of	each	sample,	 and	 performs	 supervised	 expression	 deconvolution	 in	 a	 set	 of	 genes	 identified	 as	informative	 on	 immune	 cell	 types,	 using	 the	 least	 squares	with	 equality/inequality	 constrains	(LSEI)	 algorithm	 with	 a	 reference	 dataset	 containing	 expected	 expression	 levels	 for	 the	 10	immune	cell	types.	Importantly,	quanTIseq	also	provides	estimates	of	the	total	proportion	of	cells	in	the	bulk	sequencing	that	do	and	do	not	belong	to	immune	cells.	We	 tested	 whether	 immune	 composition	 differed	 between	 histopathological	 types,	 LNET	clusters,	LNEN	clusters,	and	supra-carcinoids	using	linear	permutation	tests	(R	package	lmperm,	v.	 2.1.0).	 Permutations	 tests	 are	 exact	 statistical	 tests	 that	 do	 not	 rely	 on	 approximations	 and	assumptions	 regarding	 the	 data	 distribution,	 and	 are	 thus	 well	 fitted	 to	 test	 whether	 a	 few	samples	come	from	the	same	distribution	as	a	larger	group	of	samples.	As	such,	they	were	well-fitted	to	handle	the	tests	involving	supra-carcinoids,	for	which	only	3	samples	had	RNA-seq	data.	For	each	of	the	three	analyses	(histopathology,	LNET	clusters,	and	LNEN	clusters),	and	for	each	pair	of	groups,	we	fitted	one	model	per	immune	cell	type,	with	the	proportion	of	this	cell	type	in	each	 sample	 as	 explained	 variable	 and	 the	 cluster	 membership	 as	 explanatory	 variable.	 We	adjusted	the	p-values	for	multiple	testing.	The	code	used	for	these	three	analyses	is	available	on	https://icbi.i-med.ac.at/software/quantiseq/doc/index.html	 and	 the	 associated	 results	 are	presented	Figures	2F	and	4B,	and	Supplementary	Figures	15,	19	and	32.		
Methylome	analyses	
EPIC	850K	methylation	array	Epigenome	 analysis	 was	 performed	 on	 33	 typical	 carcinoids,	 23	 atypical	 carcinoids,	 and	 20	LCNEC,	 plus	 19	 technical	 replicates.	 Epigenomic	 studies	 were	 performed	 at	 the	 International	Agency	 for	 Research	 on	 Cancer	 (IARC)	 with	 the	 Infinium	 EPIC	 DNA	 methylation	 beadchip	platform	(Illumina)	used	for	the	interrogation	of	over	850,000	CpG	sites	(dinucleotides	that	are	the	main	target	for	methylation).	Each	chip	encompasses	8	samples,	so	12	chips	were	needed	for	the	95	samples.	We	used	stratified	randomization	to	mitigate	the	batch	effects,	ensuring	that	the	three	 histopathological	 types	 were	 present	 on	 every	 chip,	 while	 also	 controlling	 for	 potential	confounders	(the	sample	provider,	sex,	smoking	status,	and	age	of	the	patient);	replicates	were	placed	on	different	chips.	For	 each	 sample,	 600	 ng	 of	 purified	 DNA	were	 bi-sulfite	 converted	 using	 the	 EZ-96	 DNA	Methylation-GoldTM	 kit	 (Zymo	 Research	 Corp.,	 CA,	 USA)	 following	 the	 manufacturer's	recommendations	for	Infinium	assays.	3	replicates	included	half	the	amount	(300ng).	Then,	200	ng	 of	 bisulfite-converted	 DNA	 was	 used	 for	 hybridization	 on	 Infinium	 MethylationEPIC	
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beadarrays,	following	the	manufacturer’s	protocol	(Illumina	Inc.).	This	array	shares	the	Infinium	HD	chemistry	(Illumina	Inc.)	and	a	similar	 laboratory	protocol	used	to	 interrogate	the	cytosine	markers	 with	 HumanMethylation450	 beadchip.	 Chips	 were	 scanned	 using	 Illumina	 iScan	 to	produce	two-colour	raw	data	files	(IDAT	format).		
Data	processing	The	 resulting	 IDAT	raw	data	 files	were	pre-processed	using	R	packages	minfi	 (v.	1.24.0)63	 and	ENmix	 (v.	 1.14.0)64.	 We	 first	 removed	 unwanted	 technical	 variation	 in-between	 arrays	 using	functional	 normalization	 of	 the	 raw	 two-colour	 intensities,	 and	 computed	 the	β-values	 for	 the	866,238	probes	and	96	samples.	Then,	we	filtered	four	types	of	probes	that	could	confound	the	analyses.	 i)	We	 removed	probes	 on	 the	X	 and	Y	 chromosomes,	 because	we	were	 interested	 in	variation	 between	 tumours	 and	 treated	 sex	 as	 a	 confounder.	 ii)	 We	 removed	 known	 cross-reactive	probes—i.e.,	probes	that	co-hybridize	to	other	chromosomes	and	thus	cannot	be	reliably	investigated.	iii)	We	removed	probes	that	had	failed	in	at	least	one	sample,	using	a	detection	p-value	 threshold	 of	 0.01,	 where	 p-values	 were	 computed	 with	 the	 detectionP	 function	 from	 R	package	minfi,	 that	 compares	 the	 total	 signal	 (methylated	+	unmethylated)	at	 each	probe	with	the	background	signal	level	from	non-negative	control	probes.	iv)	We	removed	probes	associated	with	common	SNPs—that	reflect	underlying	polymorphisms	rather	than	methylation	profiles—using	 a	 threshold	 minor	 allele	 frequency	 of	 5%	 in	 database	 dbSNP	 build	 137	 (function	dropLociWithSnps	 from	minfi).	v)	We	removed	probes	putatively	associated	with	rare	SNPs	by	detecting	and	removing	probes	with	multimodal	β-value	distributions	(function	nmode.mc	from	R	 package	 ENmix).	 Next,	we	 removed	 duplicated	 samples,	 randomly	 choosing	 one	 sample	 per	pair	 so	 as	 to	minimize	potential	 discrepancies,	 and	we	 removed	one	 sample	 that	 came	 from	a	metastatic	 tumour	rather	 than	a	primary	 tumour	 (sample	not	 reported	 in	 the	study).	The	 final	dataset	contained	the	β-values	of	767,781	CpGs	for	76	samples.	We	performed	quality	controls	of	the	raw	data.	Two-colour	intensity	data	of	internal	control	probes	 were	 inspected	 to	 check	 the	 quality	 of	 successive	 sample	 preparation	 steps	 (bisulfite	conversion,	 hybridization).	 We	 did	 not	 find	 outliers	 when	 comparing	 the	methylated/unmethylated	 channel	 intensities	 of	 all	 samples,	 nor	 did	 we	 find	 samples	 with	overall	 low	detection	p-values	(the	sample	with	the	lowest	mean	p-value	had	a	value	of	0.001).	Concordance	between	the	sex	reported	in	the	clinical	data	and	the	methylation	data	was	assessed	using	a	predictor	based	on	the	median	total	intensity	on	sex-chromosomes,	with	a	cutoff	of	-2	log2	estimated	 copy	 number	 (function	 getSex	 from	minfi).	 Consistently	with	 the	WES	 and	RNA-seq	data,	we	 found	one	sample	with	a	mismatch	between	reported	and	 inferred	sex	(see	results	 in	
Supplementary	Figure	28C).	We	investigated	batch	effects	at	the	raw	data	level	using	surrogate	variable	 analysis.	 We	 used	 function	 ctrlsva	 from	 package	 ENmix	 to	 compute	 a	 principal	component	analysis	of	the	intensity	data	from	non-negative	control	probes.	We	retained	the	first	10	 principal	 components—hereafter	 referred	 to	 as	 surrogate	 variables—explaining	more	 than	90%	of	 the	 variation	 in	 control	 probes	 intensity.	 The	 10	 surrogate	 variables	were	 included	 as	covariables	in	later	supervised	analyses	to	mitigate	the	impact	of	batch	effects	on	the	results.	We	
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checked	the	association	of	surrogate	variables	with	batch	(chip,	position	on	the	chip,	and	sample	provider)	 and	 clinical	 variables	 (histopathological	 type,	 age,	 sex,	 smoking	 status)	 using	 PCA	regression	 analysis,	 fitting	 separate	 linear	models	 to	 each	 surrogate	 variable	with	 each	 of	 the	seven	 covariables	 of	 interest	 and	 adjusted	 the	 p-values	 for	 multiple	 testing.	 We	 show	 in	
Supplementary	Figure	33A	that	surrogate	variables	1,	2,	3,	and	10	are	significantly	associated	with	 the	 chip	 (variable	 Sentrix	 id)	 or	 position	 on	 the	 chip	 (variable	 Sentrix	 position),	 while	surrogate	variables	4,	5,	and	10	are	significantly	associated	with	the	sample	provider.	The	code	used	 to	 perform	 all	 the	 pre-processing	 procedure	 of	 these	 data	 is	 available	 at	https://github.com/IARCbioinfo/Methylation_analysis_scripts.		
Unsupervised	Analysis	of	methylation	data	The	 β-values	 of	 767,781	 CpGs	 for	 76	 samples	 were	 transformed	 into	 M-values	 to	 perform	unsupervised	analyses;	indeed,	contrary	to	β-values,	M-values	theoretically	range	from	-∞	to	+∞	and	are	considered	normally-distributed.	We	performed	two	analyses,	with	different	subsets	of	samples:	 i)	 an	analysis	with	all	 carcinoid	and	LCNEC	samples	 (76	samples),	 and	 ii)	 an	analysis	with	carcinoid	samples	only	(56	samples).	For	each	analysis,	the	most	variable	CpGs	(explaining	5%	of	the	total	variance	in	M-values)	were	selected	(8483	and	7693	CpGs,	respectively,	for	i	and	ii).	PCA	was	then	performed	independently	for	each	analysis	(function	dudi.pca	from	R	package	
ade4	v1.7-8)61.	Results	are	presented	in	Supplementary	Figure	7;	see	the	Multi-omic	integration	section	 of	 the	 methods	 for	 a	 comparison	 of	 the	 results	 of	 the	 unsupervised	 analysis	 of	methylation	data	with	that	of	the	other	omics.	We	 used	 the	 results	 from	 the	 PCA	 to	 detect	 outliers	 and	 batch	 effects	 in	 the	methylation	dataset.	We	did	not	detect	any	outliers	in	any	of	the	analyses	from	Supplementary	Figure	7.	We	also	 performed	 a	 PCA	 regression	 analysis	 using	 the	 same	 protocol	 as	 described	 in	 the	 data	processing	section	above.	Results	highlighted	no	association	between	any	principal	 component	and	 array	 batches	 (chip	 and	 position	 in	 the	 chip;	 Supplementary	 Figure	 33A).	 Principal	component	 2	 was	 associated	 with	 the	 sample	 provider;	 further	 examination	 of	 the	 PCA	(Supplementary	Figure	33B)	revealed	that	this	effect	was	driven	by	the	samples	from	provider	1,	which	have	 the	 largest	 range	of	 coordinates	 on	PC2	 (from	 less	 than	 -30	 to	more	 than	100).	Nevertheless,	 the	 fact	 that	 their	 coordinates	 on	 PC2	 overlap	 with	 that	 of	 samples	 from	 other	providers,	 and	 the	 fact	 that	 the	 vast	 majority	 of	 atypical	 carcinoid	 samples	 come	 from	 one	provider,	 suggest	 that	 the	 large	 range	of	values	of	provider	1	 samples	on	PC2	 is	driven	by	 the	biological	variability	of	carcinoid	methylation	profiles.	In	addition,	note	that	samples	that	cluster	with	LCNEC	are	not	solely	from	provider	1.	We	assessed	the	impact	of	functional	normalization	on	batch	effects	by	performing	the	same	analysis	on	the	M-values	of	the	5%	most	variable	CpGs	obtained	without	normalization	(Supplementary	Figure	33A).	Compared	to	the	PCA	of	the	5%	most	 variable	 CpGs	 with	 normalization	 (Supplementary	 Figure	 33A),	 we	 find	 that	 the	 chip	position	 (variable	 Sentrix	 position)	 is	 significantly	 associated	 with	 PC10,	 and	 that	 PC2	 is	 not	associated	with	 histopathology.	 This	 suggests	 that	 the	 functional	 normalization	 reduced	 batch	
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effects	and	revealed	some	of	the	biological	variability	in	methylation	data.	The	 PCA	 is	 also	 informative	 about	 associations	 between	methylation	 profiles	 and	 clinical	variables.	We	find	a	significant	association	between	PC1,	histopathological	type,	age,	and	smoking	status,	 with	 LCNEC,	 smokers,	 and	 larger	 age	 classes	 located	 at	 higher	 PC1	 coordinates	(Supplementary	 Figure	 33A);	 these	 associations	 are	 expected,	 given	 that	 the	 difference	between	LCNEC	and	Carcinoids	is	expected	to	be	the	main	driver	of	variation	in	methylation,	and	given	known	the	aetiology	of	the	diseases8.	We	find	an	association	between	principal	component	2,	 histopathology,	 and	 sex,	 with	 male	 and	 atypical	 carcinoids	 having	 overall	 larger	 PC2	coordinates.	We	find	associations	of	larger	components,	in	particular	PC3	and	age,	and	PC7	and	9	and	sex.		
Supervised	Analysis	of	methylation	data	We	detected	differential	methylation	at	the	probe	level	(DMP)	in	three	independent	analyses:	i)	between	histopathological	types	(TC,	AC,	and	LCNEC),	ii)	between	LNET	clusters	(clusters	A1,	A2,	and	B),	and	iii)	between	LNEN	clusters	(clusters	A,	B,	and	LCNEC).	To	detect	DMPs,	for	each	analysis,	linear	models	were	first	fitted	independently	for	each	CpG	to	 its	M-values	 (function	 lmFit	 from	 R	 package	 limma	 version	 3.34.9)65,	 using	 the	 variable	 of	interest	(histopathology,	LNET	cluster,	or	LNEN	cluster),	in	addition	to	the	sex,	age	group,	and	the	10	 surrogate	 variables	 as	 covariables.	 Then,	 moderated	 t-tests	 were	 performed	 by	 empirical	Bayes	moderation	 of	 the	 standard	 errors	 (function	 eBayes	 from	package	 limma),	 and	p-values	were	computed	for	each	CpG.	Moderation	enables	to	increase	the	statistical	power	of	the	test	by	increasing	the	effective	degrees	of	freedom	of	the	statistics,	while	also	reducing	the	false	positive	rate	 by	 protecting	 against	 hypervariable	 CpGs,	 and	 are	 thus	 favored	 in	 array	 analyses.	 The	 p-values	were	adjusted	for	multiple	testing,	and	CpGs	with	a	q-value	lower	than	0.05	were	retained.	The	code	used	for	the	DMPs	identification	(DMP.R)	is	available	in	the	Supplementary	Software	
1	and	the	associated	results	of	analyses	(i),	(ii),	and	(iii)	are	presented	Supplementary	Tables	
16,	 Supplementary	 Tables	 11,	 and	 17,	 respectively.	 See	 section	 Multi-omics	 integration	 for	comparisons	between	the	analyses	based	on	histopathological	types	(analysis	(i))	from	all	‘omics	perspectives.	Analysis	(iii)	confirmed	most	DMPs	associated	with	DEGs	reported	in	Figure	5A	for	cluster	B	relative	to	LNET	clusters	(TFF1,	OTOP3,	SLC35D3,	APOBEC2)	were	also	DMPs	for	cluster	B	relative	to	LNEN	clusters,	showing	that	they	harboured	specific	methylation	levels	that	made	them	different	from	the	LCNEC	cluster	as	well	as	from	other	carcinoid	clusters.		
Multi-omics	integration	
Data	We	performed	an	 integrative	analysis	of	 the	WES,	WGS,	RNA-seq,	 and	850K	methylation	array	data,	using	 the	validated	 somatic	mutations	 (Supplementary	Table	4),	 the	variance-stabilized	read	counts,	and	the	M-values,	respectively.	The	full	dataset	consisted	of	243	samples,	but	some	analyses	focused	on	a	subset	of	the	data.	
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Unsupervised	analyses	Continuous	latent	factors	identification.	We	performed	an	integrative	group	factor	analysis	of	the	expression	and	methylation	data	using	software	MOFA	(R	package	MOFAtools	v.	0.99)16.	MOFA	identifies	 latent	 factors	 (LF,	 i.e.,	 continuous	 variables)	 that	 explain	most	 variation	 in	 the	 joint	datasets.	 We	 did	 not	 include	 the	 somatic	 mutations	 in	 the	 model	 because	 the	 low	 level	 of	recurrence	(only	4	recurrently-mutated	genes	in	Supplementary	Table	4)	resulted	in	a	sample	by	mutation	matrix	of	much	lower	dimension	than	the	other	‘omics,	which	is	known	to	bias	the	analyses16.	 Also,	 we	 did	 not	 consider	 expression	 and	methylation	 from	 the	 sex	 chromosomes,	because	 we	 were	 interested	 in	 differences	 between	 tumours	 independently	 of	 the	 sex	 of	 the	patient.	We	performed	four	analyses,	with	different	subsets	of	samples.	 i)	An	analysis	with	all	235	samples	for	which	expression	or	methylation	data	was	available	(LNEN	and	SCLC),	ii)	an	analysis	with	LNEN	samples	only	(183	samples),	iii)	an	analysis	with	LNET	and	SCLC	samples	only	(163	samples),	and	iv)	an	analysis	with	LNET	samples	only	(111	samples).	For	each	analysis,	the	most	variable	genes	for	expression	(explaining	50%	of	the	total	variance)	were	selected	(6398,	6009,	6234,	and	5490	genes,	respectively,	for	i,	ii,	iii,	and	iv),	and	the	most	variable	CpGs	(explaining	5%	of	the	total	variance)	were	selected	(8483,	8483,	7693,	and	7693	CpGs,	respectively,	for	i,	 ii,	 iii,	and	 iv).	Note	 that	 these	 lists	 of	 genes	 and	CpGs	are	 the	 same	as	 the	ones	used	 to	perform	 the	unsupervised	 analyses	 of	 expression	 and	methylation	 data	 (see	 sections	 RNA	 sequencing	 and	EPIC	850k	methylation	array).	Also	note	that	we	did	not	have	EPIC	850k	methylation	array	data	for	 SCLC;	 MOFA	 was	 shown	 to	 handle	 missing	 data,	 including	 samples	 with	 entire	 ‘omic	techniques	missing,	 by	 using	 the	 correlated	 signals	 from	 several	 datasets	 (e.g.,	 expression	 and	methylation)	 to	 accurately	 reconstruct	 latent	 factors.	MOFA	was	 performed	 independently	 for	each	 analysis,	 setting	 the	 number	 of	 latent	 factors	 to	 5,	 because	 subsequent	 latent	 factors	explained	less	than	2%	of	the	variance	of	both	‘omic	datasets	(function	runMOFA	from	R	package	MOFAtools	v0.99.0).	Because	MOFA	uses	a	heuristic	algorithm,	we	assessed	the	robustness	of	the	results	 using	 20	MOFA	 runs.	 	We	 then	 computed	 the	 correlations	 between	 each	 of	 the	 5	 first	latent	 factors	 across	 each	 run,	 resulting	 in	 a	 correlation	 matrix	 of	 100	 by	 100	 entries	(Supplementary	Figures	2	and	17).	We	found	that	the	correlations	across	runs	were	very	high	(>0.95	 for	>80%	of	runs)	 in	all	analyses,	suggesting	that	 the	results	are	robust.	 In	addition,	we	found	 that	 correlations	 between	 latent	 factors	 within	 runs	 were	 small	 (typically	 below	 0.2),	which	suggests	that	latent	factors	capture	quasi-independent	sources	of	variation	in	the	datasets.	For	each	analysis,	we	selected	the	MOFA	run	that	resulted	in	the	best	convergence,	based	on	the	evidence	 lower	 bound	 statistic	 (ELBO).	 Results	 are	 presented	 in	 Figures	 1A,	 4A,	 and	
Supplementary	Figure	13.	Interestingly,	we	find	that	MOFA	latent	factors	1	to	3	for	analysis	(i)	(LNET,	LCNEC,	and	SCLC)	correspond	to	MOFA	LF	2	to	4	for	analysis	(ii)	(LNET	and	LCNEC),	and	to	MOFA	LF	3	to	5	for	analysis	(iv)	(LNET	alone);	this	suggests	that	each	histopathological	type	introduces	 an	 independent	 source	 of	 variation,	 resulting	 in	 a	 new	 LF.	 The	 code	 used	 for	 the	
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unsupervised	 continuous	 molecular	 analyses	 (integration_MOFA.R)	 is	 available	 on	https://github.com/IARCbioinfo/integration_analysis_scripts.		Comparison	with	uni-omic	unsupervised	analyses.	We	compared	the	results	of	MOFA	with	that	of	the	unsupervised	analysis	of	expression	and	methylation	data	(Supplementary	Figure	3).	To	do	so,	we	used	the	51	LNEN	samples	for	which	we	had	both	expression	and	methylation	data,	and	extracted	 their	 coordinates	 in	 MOFA,	 expression	 PCA	 (see	 section	 unsupervised	 analysis	 of	expression	data),	and	methylation	PCA	(see	section	unsupervised	analysis	of	methylation	data).	When	using	LNET	and	LCNEC	samples	(Supplementary	Figure	3A),	we	found	that	MOFA	LF1	is	strongly	correlated	with	expression	PC1	and	methylation	PC1	(|r|>0.98;	Supplementary	Figure	
3D	and	E),	and	that	expression	PC1	and	methylation	PC1	are	strongly	correlated	between	them	(r=0.97;	Supplementary	Figure	3C);	LF2	was	strongly	correlated	with	expression	PC3	(r=-0.86;	
Supplementary	 Figure	 3P),	 and	 methylation	 PC2	 (r=-0.98;	 Supplementary	 Figure	 3K),	suggesting	 that	 LF2	 is	 more	 driven	 by	 methylation	 differences,	 but	 that	 it	 is	 nonetheless	consistent	 with	 a	 large	 proportion	 of	 expression	 variation.	 On	 the	 contrary,	 LF3	 was	 more	strongly	 correlated	 with	 expression	 PC2	 (r=0.87;	 Supplementary	 Figure	 3J),	 suggesting	 that	PC3	is	more	driven	by	expression	differences.	All	these	observations	are	consistent	with	the	fact	that	the	percentage	of	variance	explained	by	LF2	and	LF3	in	terms	of	expression	and	in	terms	of	methylation	are	different:	LF2	explains	more	expression	in	methylation,	while	LF3	explains	more	variation	in	expression	(Figure	1A);	it	is	also	coherent	with	the	fact	that	clusters	A1	and	A2	are	the	most	separated	clusters	on	expression	PC2	(Supplementary	Figure	6B),	while	clusters	A1	and	 B	 are	 the	 most	 separated	 on	methylation	 PC2	 (Supplementary	 Figure	 7A).	 When	 using	LNET	samples	only	(Supplementary	Figure	3B),	we	found	that	MOFA	LF1	is	strongly	correlated	with	expression	PC2	and	methylation	PC1	(|r|>0.86;	Supplementary	Figure	3M	and	H),	and	that	expression	 PC2	 and	 methylation	 PC1	 are	 strongly	 correlated	 between	 them	 (r=0.72;	
Supplementary	 Figure	 3F);	 LF2	 was	 strongly	 correlated	 with	 expression	 PC1	 (r=-0.88;	
Supplementary	 Figure	 3G),	 and	 methylation	 PC2	 (r=0.90;	 Supplementary	 Figure	 3N),	suggesting	 that	 LF2	 is	 more	 driven	 by	 methylation	 differences,	 but	 that	 it	 is	 nonetheless	consistent	 with	 a	 large	 proportion	 of	 expression	 variation.	 Again,	 all	 these	 observations	 are	consistent	with	 the	 fact	 that	 the	percentage	 of	 variance	 explained	by	 LF1	 and	LF2	 in	 terms	of	expression	and	in	terms	of	methylation	are	different	(Figure	4A);	it	is	also	coherent	with	the	fact	that	 clusters	 A1	 and	 A2	 are	 the	most	 separated	 clusters	 on	 expression	 PC1	 (Supplementary	
Figure	 6D),	 while	 clusters	 A1	 and	 B	 are	 the	 most	 separated	 on	 methylation	 PC2	(Supplementary	Figure	7B).		Associations	 of	 latent	 factors	 with	 other	 variables.	We	 used	 the	 results	 from	MOFA	 to	 detect	outliers	 and	batch	 effects	 in	 the	dataset.	We	did	not	detect	 any	outliers	 in	 any	of	 the	 analyses	from	Supplementary	Figure	13.	We	 further	 studied	 the	 associations	 between	 the	 first	 5	 LFs,	batch	 (sample	 provider),	 and	 5	 clinical	 variables	 of	 interest	 (histopathological	 type,	 age,	 sex,	
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smoking	 status,	 and	 stage)	 using	 regression	 analysis.	 For	 each	 latent	 factor,	we	 fitted	 a	 linear	model	with	 the	6	covariables	of	 interest	(provider	plus	 the	5	clinical	variables).	Because	of	 the	reported	 association	 between	 sex,	 age,	 and	 smoking	 status,	we	 also	 included	 in	 the	model	 the	interaction	between	sex	and	smoking	status	and	between	age	and	smoking	status;	we	adjusted	the	resulting	p-values	for	multiple	testing.	Significant	associations	(q-value<0.05)	are	highlighted	in	Figs.	1A	and	4A.	We	 also	 tested	 the	 association	 between	 MOFA	 clusters	 and	 mutations	 using	 regression	analysis.	 We	 tested	 genes	 recurrently	 mutated	 in	 carcinoids,	 using	 a	 threshold	 of	 3	 samples	(following	 Argelaguet	 et	 al.	 2017)16;	 indeed,	 non-recurrent	 genes	 are	 not	 informative	 about	molecular	 groups.	 Only	 two	 genes	 were	 retained:	 MEN1	 and	 EIF1AX.	 We	 also	 included	recurrently	mutated	genes	reported	in	LCNEC12.	Results	are	highlighted	in	Figure	4A.	Similarly,	we	 tested	 the	association	between	pathways	highlighted	 in	Supplementary	Figure	16	 (Lysine	demethyltransferases,	 polycomb	 complex,	 SWI/SNF	 complex)	 and	 MOFA	 LF	 using	 regression	analysis,	but	did	not	find	any	significant	association	at	a	false	discovery	rate	threshold	of	0.05.		Clustering.	 We	 identified	 molecular	 clusters—groups	 of	 samples	 with	 similar	 molecular	profiles—from	MOFA	 results.	 Following	Mo	 et	 al,	 PNAS,	 (2013)66,	 given	 a	 specified	 number	 of	clusters	 K,	 we	 used	 the	 K-1	 latent	 factors	 that	 explained	 most	 of	 the	 variation	 to	 perform	clustering;	 this	 choice	 of	 number	 of	 latent	 factors	 in	Mo	 et	 al,	 PNAS	 66	 is	 said	 to	 be	 primarily	motivated	 by	 “a	 general	 principle	 for	 separating	 g	 clusters	 among	 the	 n	 datapoints,	 a	 rank-k	approximation	 where	 k≤g−1	 is	 sufficient.”	 In	 addition,	 because	 the	 MOFA	 latent	 factors	explaining	the	most	variance	in	gene	expression	and	methylation	are	expected	to	capture	more	biological	signal	compared	to	the	ones	explaining	the	least	variance—expected	to	represent	more	of	the	noise	in	the	dataset—,	we	expect	that	using	the	first	K-1	latent	factors	would	provide	more	biologically	meaningful	clusters	than	using	all	latent	factors.	In	addition,	following	the	procedure	from	Wilkerson	and	Hayes	Bioinformatics	(2010)67,	we	performed	consensus	clustering	to	detect	robust	 molecular	 clusters.	 This	 procedure	 involved	 multiple	 replicate	 clusterings	 (K-means	algorithm;	R	function	kmeans),	each	on	latent	factors	from	an	independent	MOFA	run	done	on	a	subsample	(80%)	of	the	data.	Pairwise	consensus	values	were	defined	as	the	proportion	of	runs	in	 which	 two	 samples	 are	 clustered	 together	 and	 used	 as	 a	 similarity	 measure,	 and	 used	 to	perform	a	final	hierarchical	clustering	(median	linkage	method).	Consensus	clustering	results	for	
K	 from	 2	 to	 5,	 for	 LNET	 plus	 LCNEC	 samples	 and	 LNET	 samples	 alone,	 are	 presented	
Supplementary	Figures	5	and	18,	respectively.	In	the	case	of	LNET	alone,	because	the	optimal	Dunn	 index,	 which	 evaluates	 the	 quality	 of	 clustering	 as	 a	 ratio	 of	within-cluster	 to	 between-cluster	distances,	 corresponded	 to	 	K	=	 3	 clusters	 (Supplementary	Figure	18C),	we	chose	 the	solution	with	3	 clusters.	Nevertheless,	note	 that	 the	 cluster	memberships	 for	K=4	and	K=5	are	almost	 perfectly	 nested	 into	 that	 for	 K=3	 (e.g.,	 samples	 from	 the	 blue	 cluster	 for	 K=3,	
Supplementary	 Figure	 18B	 are	 split	 between	 a	 blue	 and	 a	 purple	 cluster	 for	 K=4),	 so	 the	solutions	with	 3	 and	4	 clusters	 are	 coherent.	 Cluster	memberships	 are	 highlighted	Figure	4A.	
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Similarly,	 in	 the	case	of	LNET	plus	LCNEC	samples	 (LNEN),	because	 the	optimal	Dunn	 index	 is	reached	when	K=3,	we	 chose	 that	 solution,	but	note	 that	 the	 cluster	memberships	 for	K>3	are	also	nested	into	that	for	K=3,	so	all	results	are	coherent	across	values	of	K.	In	order	to	test	whether	using	additional	 latent	 factors	could	 increase	the	power	to	detect	molecular	 clusters,	we	performed	 a	 similar	 analysis	 but	 using	 all	 5	 latent	 factors	 identified	 by	MOFA.	In	order	to	provide	more	importance	to	the	factors	most	 likely	to	capture	the	biological	variation	 in	 the	 data,	 the	 multiple	 replicate	 clusterings	 were	 performed	 using	 a	 weighted	 k-means	algorithm,	where	variables	(here	MOFA	latent	factors)	are	given	weights	corresponding	to	their	proportion	of	variance	explained.	More	specifically,	instead	of	minimizing	the	within-cluster	sum	 of	 squares,	 the	 weighted	 within-cluster	 sum	 of	 squares	 is	 minimized.	 	 Results	 for	 K=3	clusters	of	LNET	and	LNEN	samples	are	presented	in	Supplementary	Figure	8.	We	can	see	that	the	alternative	approach	(weighted	K-means	on	5	latent	factors)	leads	to	the	exact	same	cluster	membership	as	the	original	approach	(K-means	on	K-1	latent	factors),	both	for	LNEN	and	LNET	clusters.	Indeed,	among	the	latent	factors,	only	the	first	3	were	associated	with	either	the	LNEN	clusters	 (ANOVA	 q	 =	 4.09x10-84,	 8.63x10-80,	 0.66,	 0.094,	 0.24,	 respectively	 for	 latent	 factors	 1	through	 5)	 or	 the	 LNET	 clusters	 (ANOVA	 q	 =	 5.06x10-4,	 5.99x10-47,	 5.12x10-46,	 0.15,	 0.052,	respectively),	 which	 indicates	 that	 the	 first	 3	 latent	 factors	 captured	 the	 differences	 between	clusters.	 The	 code	used	 for	 the	 clustering	 analyses	 (integration_unsupervised.R)	 is	 available	 at	https://github.com/IARCbioinfo/integration_analysis_scripts.		GSEA	 of	 features	 associated	 with	 latent	 factors.	 We	 performed	 Gene	 set	 enrichment	 analysis	(GSEA)	 on	 the	 latent	 factors	 identified	 by	 MOFA	 using	 the	 built-in	 function	FeatureSetEnrichmentAnalysis	16.	This	tests	for	each	latent	factor	whether	the	distribution	of	the	loadings	of	 features	 (genes	or	CpGs)	 from	a	 focal	 set	are	significantly	different	 from	the	global	distribution	 of	 loadings	 from	 features	 outside	 the	 set.	 We	 performed	 the	 analysis	 using	 two	reference	 databases	 of	 gene	 sets:	 GO	 and	KEGG.	 To	 retrieve	 the	 appropriate	 databases,	 for	 all	genes	 from	 the	 muti-omics	 integration	 analysis,	 we	 downloaded	 GO	 terms	 using	 R	 package	biomaRt68,	 and	we	 retrieved	KEGG	pathways	using	R	package	KEGGgraph	 (v.	1.38.0)69.	Results	are	presented	Supplementary	Table	6.		
Expression	and	methylation	correlation	analysis	We	performed	correlation	tests	in	two	analyses:	i)	between	LNET	clusters	(clusters	A1,	A2,	and	B),	and	ii)	between	LNEN	clusters	(clusters	A,	B,	and	LCNEC).	We	selected	for	each	gene,	the	set	of	CpGs	 in	 the	 region	 −2000	 to	 +2000	 from	 the	 transcription	 start	 site	 (TSS)	 using	 function	getnearestTSS	 from	 R	 package	 FDb.InfiniumMethylation.hg19	 version	 2.2.0based	 on	 the	IlluminaHumanMethylationEPICanno.ilm10b2.hg19	 annotation	 (getAnnotation	 function	 from	 R	package	minfi	version	1.24.0)63.	We	 performed	 correlation	 test	 analyses	 (function	 cor.test	 from	 R	 package	 stats	 version	3.5.1)	 using	 the	 core	 genes	 lists	 (Supplementary	 Tables	 10	 and	 12)	 to	 find	 associations	
31		
between	expression	and	methylation	data	 for	each	CpG,	using	Pearson's	correlation	coefficient.	The	p-values	were	adjusted	for	multiple	testing.	In	addition,	we	explored	the	correlation	between	expression	and	methylation	data	by	fitting	linear	model	independently	for	each	correlated	CpGs	(function	lm	from	R	package	stats	version	3.5.1).	Finally,	we	calculated	the	interquartile	distance	of	β-values	 for	each	CpG.	CpGs	with	a	q-value<0.05,	r2>0.5	and	an	 interquartile	distance	higher	than	0.25	were	retained	and,	among	these	CpGs,	only	the	one	with	the	smallest	q-value	has	been	represented	 in	 Supplementary	 Figure	 22.	 Results	 of	 analyses	 (i)	 and	 (ii)	 are	 reported	 in	
Supplementary	Tables	10	and	12.		
Survival	analysis	using	penalized	generalized	linear	model.	We	computed	a	generalized	linear	model	with	elastic	net	regularization	(R	package	glmnet	v2.0-16)70	to	select	the	genes	associated	with	the	survival	of	LNET	samples.	We	fixed	the	elastic	net	mixing	 parameter	 α	 to	 0.5	 and	 used	 leave-one-out	 cross-validation	 to	 determine	 the	regularization	parameter	λ	(cv.glmnet	function	from	glmnet	package).	To	be	more	stringent,	the	optimal	 regularization	 parameter	 chosen	 was	 the	 one	 associated	 with	 the	 most	 regularized	model	with	 cross-validation	 error	within	 one	 standard	 deviation	 of	 the	minimum.	 In	 order	 to	identify	the	genes	associated	with	the	poor	survival	of	the	cluster	Carcinoid	B,	we	included	in	the	model	only	the	expression	of	the	core	genes	of	this	cluster	defined	in	the	MOFA	considering	only	the	 LNET	 samples	 (see	 section	Multi-omics	 integration).	We	used	 the	 normalized	 read	 counts,	and	 centered	 and	 scaled	 them	 using	 R	 package	 caret	 (v6.0-80).	 The	 genes	 with	 non-zero	estimated	 coefficients	 are	 listed	 in	 Supplementary	 Table	 13.	 	 For	 each	 non-coding	 gene,	 we	determined	the	optimal	cutpoint	of	expression	(normalized	read	counts)	that	best	separates	the	survival	 outcome	 into	 two	 groups	 using	 the	 surv_cutpoint	 function	 based	 on	 the	 maximally	selected	 rank	 statistics	 and	 available	 in	 the	 R	 package	 survminer	 (v0.4.3).	 The	 minimal	proportion	of	samples	per	group	was	set	to	10%.		
Supervised	analyses	We	performed	supervised	learning	in	order	to	classify	typical	and	atypical	carcinoids,	and	LCNEC	based	on	the	different	omics	data	available:	expression	and	methylation	data.	Classification	algorithm.	Each	 classification	was	performed	using	a	 random	 forest	 algorithm	 (R	package	randomForest	v4.6-14).	Considering	the	restricted	number	of	samples,	we	performed	a	leave-one-out	 cross	 validation.	 For	 each	 run,	 to	 increase	 the	 training	 set	 size,	minority	 classes	were	oversampled	so	that	all	classes	reach	the	same	number	of	 training	samples.	Note	that	 for	the	 sample	with	 technical	 replication	 of	 RNA-seq	 data	 (S00716_A	 and	 S00716_B),	 in	 order	 to	avoid	model	overfitting,	 the	 two	 replicates	were	never	 simultaneously	 included	 in	 the	 training	and	 test	 sets.	Also	 in	order	 to	 avoid	overfitting,	we	performed	normalization	 and	 independent	feature	 filtering	 within	 each	 fold,	 so	 that	 test	 samples	 were	 excluded	 from	 this	 step.	 More	specifically,	 for	the	expression	data,	the	features	of	the	training	set	were	first	normalized	using	the	 variance	 stabilization	 transformation	 (vst	 function	 from	 R	 package	 DESeq2	v1.22.2),	 then	
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mean-centered	and	scaled	to	unit	variance.	Then,	the	variance	stabilizing	transformation	learned	from	the	training	set	was	applied	to	the	test	set	using	the	dispersionFunction	function	from	the	DESeq2	package,	 and	centering	and	scaling	were	performed	using	 the	values	 learned	 from	 the	training	 set.	 For	 the	methylation	data,	 the	M	values	were	 computed	using	 the	R	package	minfi	(v1.28.3);	the	features	of	the	training	set	were	mean-centered	and	scaled	to	unit	variance,	then	the	test	sample	features	were	centered	and	scaled	using	the	values	learned	from	the	training	set.	For	each	fold	of	the	leave	one	out,	the	training	set	was	used	for	the	feature	selection.	Based	on	the	training	 set,	 we	 selected	 the	 most	 variable	 features,	 representing	 50%	 and	 5%	 of	 the	 total	variation	 in	 expression	 and	 methylation	 data	 respectively.	 The	 code	 used	 for	 the	 machine	learning	 analyses	 (ML_functions.r)	 is	 available	 in	 the	 Supplementary	 Software	 1	 and	 the	associated	results	are	reported	in	Supplementary	Table	1.		Defining	 an	 Unclassified	 category.	 The	 random	 forest	 algorithm	 provides	 for	 each	 predicted	sample	the	class	probabilities.	We	considered	a	sample	as	unclassifiable	(Unclassified	category)	if	the	 ratio	 of	 the	 two	 highest	 probabilities	 was	 below	 1.5.	 In	 fact,	 this	 threshold	 allowed	 us	 to	identify	 a	 category	 of	 samples	 with	 intermediate	 molecular	 profiles,	 for	 which	 the	 algorithm	assigns	similar	probabilities	to	the	two	most	probable	classes.	Because	of	the	small	sample	size,	this	 parameter	 was	 chosen	 a	 priori	 and	 not	 tuned	 in	 order	 to	 avoid	 overfitting.	 In	
Supplementary	 Figure	 10,	 we	 compared	 the	 classification	 results	 when	 considering	 three	different	thresholds:	1	(which	corresponds	to	no	ratio	and	results	in	few	unclassified	samples,	i.e	only	discordant	expression	and	methylation-based	predictions,	see	Integration	of	expression	and	methylation	data	below),	1.5	(which	corresponds	to	 the	ratio	reported	 in	 the	main	text),	and	3	(which	corresponds	to	a	very	stringent	ratio	resulting	in	more	unclassified	samples).	Except	for	the	size	of	the	unclassified	classes	that	depends	on	the	ratio	used,	the	confusion	matrices	for	the	three	ratios	were	qualitatively	similar,	with	most	LCNEC	samples	correctly	classified,	a	majority	of	 typical	correctly	classified,	and	almost	as	many	atypical	classified	as	typical	and	classified	as	atypical.	 In	 addition,	 the	 survival	 analyses	 of	 the	 three	models	 also	 led	 to	 similar	 conclusions,	with	atypical	carcinoids	classified	as	atypical	by	the	machine	learning	having	a	survival	that	is	not	statistically	significantly	different	from	that	of	LCNEC	samples	but	that	is	lower	from	both	that	of	typical	 carcinoids	 predicted	 as	 typical	 carcinoids,	 and	 that	 of	 atypical	 predicted	 as	 typical.	However,	in	the	case	of	the	largest	ratio,	the	small	number	of	atypical	samples	predicted	in	those	categories	did	not	enable	the	identification	of	two	groups	of	atypical	carcinoids	with	significant	different	overall	survival	(p=0.086).		Number	of	samples	and	features.	To	classify	LCNEC	against	atypical	and	typical	carcinoids,	157	and	76	samples	were	considered	using	 the	expression	and	methylation	data	 respectively.	 	The	number	of	features	selected	in	each	fold	of	the	leave-one-out	are	of	the	order	of	6000	and	8000	for	 expression	 and	 methylation	 features	 respectively.	 	 For	 the	 analysis	 based	 on	MKI67	 only	(Supplementary	 Figure	 31C,	 left	 panel),	 the	 only	 feature	 considered	 was	 the	 expression	 of	
MKI67.	
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	Integration	of	expression	and	methylation	data.	Because	 the	random	forest	algorithm	does	not	handle	missing	data	directly,	and	because	only	51	out	of	182	LNEN	samples	had	both	expression	and	 methylation	 data	 available	 (Supplementary	 Figure	 1),	 we	 performed	 random	 forest	classification	on	expression	and	methylation	separately,	and	merged	the	classification	results	by	combining	 the	 two	 sets	 of	 ML	 predictions.	 Thus,	 the	 samples	 with	 both	 expression	 and	methylation	 data	 were	 associated	 with	 two	 predictions.	 When	 the	 two	 predictions	 were	discordant	we	applied	the	following	rules:	i)	if	one	prediction	was	Unclassified	(see	Defining	an	Unclassified	 category	 above)	 and	 the	 other	 a	 histopathological	 category,	 we	 chose	 the	histopathological	category	 ii)	 if	 the	 two	predictions	were	different	histopathological	categories,	we	chose	the	Unclassified	category.	Note	that	fitting	independent	random	forest	models	on	each	dataset	separately	corresponds	to	maximizing	the	number	of	samples	(n)	per	model	at	the	expense	of	the	number	of	features	(p),	because	 each	 model	 relies	 only	 on	 the	 number	 of	 features	 in	 a	 single	 dataset.	 An	 alternative	approach	is	to	maximize	the	number	of	features	(p)	by	combining	both	datasets,	at	the	expense	of	the	 number	 of	 samples	 n,	 because	 of	 the	 limited	 number	 of	 samples	 with	 both	 data	 types	available.	 Indeed,	 for	 fixed	 n	 increasing	 p	 requires	 less	 parameters	 and	 leads	 to	 a	 higher	statistical	power.	Nevertheless,	 in	our	case,	because	of	missing	data,	 increasing	p	by	using	both	omics	 layers	 would	 drastically	 reduce	 n,	 restricting	 our	 sample	 set	 (n=157	 and	 n=76	 for	expression	and	methylation,	respectively)	to	the	set	of	samples	with	both	layers	(n=51,	including	only	 a	 single	 supra-carcinoid).	 Given	 the	 existence	 of	 very	 rare	 entities	 such	 as	 the	 supra	carcinoids,	 accurately	 capturing	 the	 diversity	 of	molecular	 profiles	 in	 the	 training	 set	was	 our	priority,	 and	 thus	 we	 chose	 to	 maximize	 n.	 In	 addition,	 by	 maximizing	 n,	 we	 hypothetically	ensured	 that	we	would	 also	maximize	 the	power	of	 the	 subsequent	 analyses	based	on	 the	ML	results.	 To	 confirm	 this	 hypothesis,	 we	 performed	 the	 ML	 analyses	 on	 the	 restricted	 set	 of	samples	 including	both	expression	and	methylation	data	 in	 the	same	model	and	compared	 the	predictions	of	this	model	to	the	combined	predictions	based	on	expression	and	methylation	data	separately.	We	found	that	the	predictions	(confusion	matrix	in	Supplementary	Figure	9)	were	similar,	 with	 43/51	 samples	 with	 both	 data	 types	 predicted	 similarly	 in	 the	 two	 models.	 In	addition,	 our	main	 finding—the	 existence	 of	 two	 groups	 of	 atypical	 samples,	which	 tended	 to	have	 a	 good	 and	 bad	 prognosis	 (red	 and	 pink	 curves	 Figure	 1B)—still	 held,	 but	 that	 limited	number	of	samples	impeded	the	statistical	analyses.	In	fact,	none	of	the	cox	regression	tests	were	significant	even	for	the	groups	displaying	the	largest	differences	(e.g	ML-predicted	LCNEC	vs	ML-predicted	 typical	 samples),	 and	 even	 when	 comparing	 the	 histological	 types	 reported	 by	 the	pathologists	 (bottom	 panel	 Supplementary	 Figure	 9).	 This	 supports	 our	 hypothesis	 that	maximizing	p	at	the	expense	of	n	 leads	to	a	decrease	in	power	in	subsequent	analyses	due	to	a	smaller	sample	size,	and	comforts	our	initial	choice.	Because	matrix	factorization	methods	such	as	MOFA	and	PCA	remove	correlations	between	features	 by	 finding	 latent	 factors	 that	 summarize	 them,	 they	 could	 presumably	 improve	 the	performance	of	ML.	Nevertheless,	by	providing	low-dimensional	approximations	of	the	data,	such	
34		
techniques	induce	a	loss	of	information,	which	could	reduce	the	performance	of	the	ML.	To	assess	the	balance	between	 these	beneficial	 and	detrimental	 effects,	we	also	performed	ML	using	 the	MOFA	factors	or	the	principal	components	of	the	PCA	analysis,	using	factors	or	components	that	explained	at	least	2%	of	the	variance	(5	MOFA	latent	factors,	6	expression	PCs,	and	5	methylation	PCs,	respectively).	These	analyses	are	presented	in	Supplementary	Figure	12	and	led	to	similar	classification	to	the	results	presented	in	the	main	text	Figure	1.	In	addition,	in	the	case	of	MOFA	factors,	 in	 accordance	with	 Figure	 1,	 atypical	 carcinoids	 were	 stratified	 into	 a	 group	with	 an	overall	survival	similar	to	that	of	the	LCNEC	(in	red)	and	a	group	with	a	higher	overall	survival	(in	pink),	similar	to	that	of	the	typical	carcinoids.	When	using	the	principal	components,	despite	a	similar	 trend,	 the	 difference	 in	 survival	 between	 the	 high-	 and	 low-survival	 groups	 was	 not	significant.	 These	 results	 show	 that	 dimensionality	 reduction	 does	 not	 lead	 to	 an	 increased	classification	ability,	nor	does	it	provide	a	better	explanation	of	clinical	behaviour.	We	thus	chose	to	represent	only	the	results	of	the	ML	analyses	based	on	expression	and	methylation	data	in	the	main	text	and	figures.		Survival	 analysis.	 We	 first	 performed	 a	 survival	 analysis	 using	 the	 predictions	 based	 on	expression	and	methylation	data.	We	divided	the	samples	into	different	groups	based	on	the	ML-predictions.	We	represented	the	Kaplan-Meier	curves	of	the	predictions	groups	by	selecting	the	groups	with	more	 than	10	 samples	 and	 gathering	 the	unclassified	 samples	 in	 the	 same	 group.		Using	Cox’s	proportional	hazard	model	and	using	 the	 logrank	 test	 statistic	 (R	package	survival	v2.42-3)	we	compared	the	overall	survival	of	LCNEC,	atypical	and	typical	samples	based	on	the	histopathological	classification	and	based	on	the	ML	predictions	(Supplementary	Figure	11A).	Forest	 plots	were	 drawn	 using	 R	 package	 survminer	 (v0.4.3).	 The	 same	 survival	 analysis	was	performed	using	 the	ML	predictions	based	on	MKI67	 expression	only	 (Supplementary	Figure	
11C).		Comparison	 between	 the	 supervised	 analyses.	 We	 contrasted	 the	 results	 of	 the	 different	supervised	 analyses	 between	 typical	 and	 atypical	 carcinoids	 based	 on	 clinical	 data,	 specific	markers	 (Ki67),	 machine	 learning,	 differential	 expression,	 and	 differential	 methylation	(Supplementary	 Figure	 31).	 Survival	 analyses	 showed	 a	 significant	 difference	 between	histopathological	 types	 (Supplementary	 Figure	 31A).	 Nevertheless,	 the	 machine	 learning	classifier	 based	 on	 the	 genome-wide	 expression	 or	 methylation	 data	 could	 not	 properly	distinguish	 atypical	 and	 typical	 carcinoids	 (Supplementary	 Figure	 31B):	 there	were	 64-83%	correctly	 classified	 typical	 carcinoids	 and	 only	 30-41%	 correctly	 classified	 atypical	 carcinoids.	The	differential	expression	analysis	showed	that	atypical	carcinoids	also	presented	very	few	core	differentially	 expressed	 genes	 (Supplementary	 Figure	 31C,middle	 panel;	 Supplementary	
Table	 15)	 and	 differentially	 methylated	 positions	 (Supplementary	 Figure	 31C,	 right	 panel;	
Supplementary	Table	17).	Overall,	 these	data	suggest	 that	 the	histopathological	classification,	although	clinically	meaningful,	does	not	completely	match	the	molecular	classification.		
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Data	availability	The	 exome	 sequencing	 data,	 RNA-seq	 data,	 and	methylation	 data	 have	 been	 deposited	 in	 the	European	 Genome-phenome	 Archive	 (EGA)	 database	which	 is	 hosted	 at	 the	 EBI	 and	 the	 CRG,	under	accession	number	EGAS#1096.	Other	datasets	 referenced	during	 the	study	are	available	from	 the	 EGA	website	 under	 accession	 numbers	 EGAS00001000650	 (pulmonary	 carcinoids)11,	EGAS00001000708	(LCNEC)12,	and	EGAS00001000925	(SCLC)13,14.	All	the	other	data	supporting	the	findings	of	this	study	are	available	within	the	article	and	its	supplementary	information	files	and	 from	 the	 corresponding	 author	 upon	 reasonable	 request.	 A	 reporting	 summary	 for	 this	article	is	available	as	a	Supplementary	Information	file.	
	
Code	availability	The	 code	 and	 software	 sources	 from	 previously	 published	 algorithms	used	 to	perform	 the	analyses	 are	detailed	in	 the	supplementary	 tables	 and	 online	 methods.	 Custom	scripts	are	provided	in	the	Supplementary	Software	1.	All	sources	for	the	software	used	in	the	manuscript	are	summarized	in	Supplementary	Table	18.		
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Figure	legends	
	
Figure	 1.	 Multi-omics	 (un)supervised	 analyses	 of	 lung	 neuroendocrine	 neoplasms.	 A)	Multi-Omics	 Factor	 Analysis	 (MOFA)	 of	 transcriptomes	 and	 methylomes	 of	 LNEN	 samples	(typical	 carcinoids,	 atypical	 carcinoids,	 and	 LCNEC).	 Point	 colours	 correspond	 to	 the	histopathological	types;	coloured	circles	correspond	to	predictions	of	histopathological	types	by	a	machine	learning	(ML)	algorithm	(random	forest	classifier)	outlined	in	Panel	B;	filled	coloured	shapes	represent	the	three	molecular	clusters	identified	by	consensus	clustering.	The	density	of	clinical	variables	that	are	significantly	associated	with	a	latent	factor	(ANOVA	q-value<0.05)	are	represented	by	kernel	density	plots	next	to	each	axis:	histopathological	type	for	 latent	factor	1,	sex	 and	histopathological	 type	 for	 latent	 factor	 2.	B)	Confusion	matrix	 associated	with	 the	ML	predictions	 represented	 on	 Panel	 A.	 The	 different	 colours	 highlight	 the	 prediction	 groups	considered	in	the	survival	analysis	and	the	colours	for	machine	learning	are	consistent	between	Panel	 B	 and	 upper	 Panel	 C.	 Black	 represents	 typical	 carcinoids	 predicted	 as	 typical,	 pink	represents	atypical	carcinoids	predicted	as	typical,	red	represents	atypical	carcinoids	predicted	as	 atypical,	 and	 blue	 represents	 LCNEC	 samples	 predicted	 as	 LCNEC.	 For	 the	 unclassified	category,	the	most	likely	classes	inferred	from	the	ML	algorithm	are	represented	by	coloured	arcs	(black	 for	 typical,	 red	 for	 atypical,	 blue	 for	 LCNEC	 and	 light	 grey	 for	 discordant	methylation-based	 and	 expression-based	 predictions).	 C)	 Kaplan-Meier	 curves	 of	 overall	 survival	 of	 the	different	ML-predictions	groups	(upper	panel)	and	histopathological	types	(lower	panel).	Upper	panel:	colours	of	predicted	groups	match	Panel	B.	Lower	panel:	black	-	typical,	red	-	atypical,	blue	-	LCNEC.	Next	to	each	Kaplan-Meier	plot,	matrix	layouts	represent	pairwise	Wald	tests	between	the	 reference	 group	 and	 the	 other	 groups,	 and	 the	 associated	 p-values;	 0.01≤p<0.05,	0.001≤p<0.01,	and	p<0.001	are	annotated	by	one,	two,	and	three	stars,	respectively.	Source	data	are	provided	in	Supplementary	Table	1.		
	
Figure	2.	Molecular	characterization	of	supra-carcinoids.	A)	Forest	plot	of	hazard	ratios	for	overall	survival	of	the	supra-carcinoids,	compared	to	carcinoid	clusters	A	and	B,	and	LCNEC.	The	number	 of	 samples	 (N)	 in	 each	 group	 is	 given	 in	 brackets.	 The	 back	 box	 represent	 estimated	hazard	 ratios	 and	 whiskers	 represent	 the	 associated	 95%	 confidence	 intervals.	 Wald	 test	 p-values	are	shown	on	the	right.	 .	B)	Enrichment	of	hallmarks	of	cancer	for	somatic	mutations	in	supra-carcinoids.	 Dark	 colours	 highlight	 significantly	 enriched	 hallmarks	 at	 the	 10%	 false	discovery	rate	threshold;	corresponding	mutated	genes	are	listed	in	the	boxes,	and	enrichment	q-values	are	reported	below.	C)	Hematoxylin	and	Eosin	(H&E)	stains	of	three	supra-carcinoids.	In	all	 cases,	 an	 organoid	 architecture	 with	 tumour	 cells	 arranged	 in	 lobules	 or	 nests,	 forming	perivascular	 palisades	 and	 rosettes	 is	 observed;	 original	 magnification	 x200.	 Arrows	 indicate	mitoses.	D)	 Radar	 charts	 of	 expression	 and	 methylation	 levels.	 Each	 radius	 corresponds	 to	 a	feature	(gene	or	CpG	site),	with	low	values	close	to	the	centre	and	high	values	close	to	the	edge.	Coloured	 lines	 represent	 the	 mean	 of	 each	 group.	 Left	 panel:	 expression	 z-scores	 of	 genes	differentially	 expressed	 between	 clusters	 Carcinoid	 A	 and	 LCNEC	 or	 between	 Carcinoid	 B	 and	
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LCNEC.	 Right	 panel:	 methylation	 β-values	 of	 differentially	 methylated	 positions	 between	Carcinoid	A	and	LCNEC	clusters	or	between	Carcinoid	B	and	LCNEC	clusters.	E)	Radar	chart	of	the	expression	z-scores	of	 immune	checkpoint	genes	(ligands	and	receptors)	of	each	group.	F)	Left	panel:	 average	proportion	of	 immune	 cells	 in	 the	 tumour	 sample	 for	 each	 group,	 as	 estimated	from	 transcriptomic	 data	 using	 software	 quanTIseq.	 Right	 panel:	 boxplot	 and	 beeswarm	 plot	(coloured	points)	of	 the	estimated	proportion	of	neutrophils,	where	 centre	 line	 represents	 the	median	and	box	bounds	represent	 the	 inter-quartile	 range	(IQR).	The	whiskers	span	a	1.5-fold	IQR	or	the	highest	and	lowest	observation	values	if	they	extend	no	further	than	the	1.5-fold	IQR.	Source	 data	 are	 provided	 in	 Supplementary	 Tables	 1,	 4,	 5,	 12,	 17,	 and	 in	 the	 European	Genome-phenome	Archive.			
Figure	 3.	 Mutational	 patterns	 of	 pulmonary	 carcinoids.	 A)	Recurrent	 and	 cancer-relevant	altered	genes	found	in	pulmonary	carcinoids	by	WGS	and	WES.	Fisher’s	exact	test	p-value	for	the	association	 between	 MEN1	 and	 the	 atypical	 carcinoid	 histopathological	 subtype	 is	 given	 in	brackets.	B)	Chimeric	 transcripts	affecting	 the	protein	product	of	DOT1L	(upper	panel),	ARID2	(middle	panel),	and	ROBO1	(lower	panel).	For	each	chimeric	transcript	the	DNA	row	represents	genes	with	their	genomic	coordinates,	the	mRNA	row	represents	the	chimeric	transcript,	and	the	protein	row	represents	the	predicted	fusion	protein.	C)	Chromotripsis	case	LNEN041,	including	an	 inter-chromosomic	 rearrangement	 between	 genes	 MEN1	 and	 SOX6.	 Upper-panel:	 copy	number	 as	 a	 function	 of	 the	 genomic	 coordinates	 on	 chromosomes	 11	 and	 20;	 a	 solid	 line	separates	 chromosomes	 11	 and	 20.	 Blue	 and	 green	 lines	 depict	 intra	 and	 inter-chromosomic	rearrangements,	respectively.	Lower	panel:	MEN1	chromosomic	rearrangement	observed	in	this	chromotripsis	case.	Source	data	are	provided	in	Supplementary	Tables	4,	7,	and	8.			
Figure	 4.	 Multi-omics	 unsupervised	 analysis	 of	 lung	 neuroendocrine	 tumours.	 A)	Multi-Omics	Factor	Analysis	(MOFA)	of	transcriptomes	and	methylomes	of	restricted	to	LNET	samples	(pulmonary	 carcinoids).	 Design	 follow	 that	 of	Figure	1A;	 filled	 coloured	 shapes	 represent	 the	three	 molecular	 clusters	 (Carcinoid	 A1,	 A2,	 and	 B)	 identified	 by	 consensus	 clustering.	 The	position	of	samples	harbouring	mutations	significantly	associated	with	a	latent	factor	(ANOVA	q-value<0.05)	are	highlighted	by	 coloured	 triangles	on	 the	axes.	B)	Upper	panel:	boxplots	of	 the	proportion	of	dendritic	cells	in	the	different	molecular	clusters	(Carcinoid	A1,	A2,	and	B)	and	the	supra-carcinoids,	 estimated	 from	 transcriptomic	 data	 using	 quanTIseq	 (Methods).	 The	permutation	test	q-value	range	 is	given	above	each	comparison:	q-value<0.001	 is	annotated	by	three	 stars.	 Lower	 panel:	 boxplots	 of	 the	 expression	 levels	 of	LAMP3	(CDLAMP)	 and	CD1A.	C)	DLL3	and	CD1A	immunohistochemistry	of	two	typical	carcinoids:	case	6	(DLL3+	and	CD1A+),	and	case	10	(DLL3-	and	CD1A-).	Upper	panels:	Hematoxylin	Eosin	Saffron	(HE)	stain.	Middle	panels:	staining	 with	 CD1	 rabbit	 monoclonal	 antibody	 (cl	 EP3622;	 VENTANA),	 where	 arrows	 show	positive	 stainings.	 Lower	 panels:	 Staining	with	DLL3	 assay	 (SP347;	 VENTANA).	D)	 Expression	levels	 of	 genes	 from	 the	 retinoid	 and	 xenobiotic	 metabolism	 pathway—the	most	 significantly	associated	 with	 MOFA	 latent	 factor	 1—in	 the	 different	 molecular	 clusters.	 Upper	 panel:	
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schematic	representation	of	the	phases	of	the	pathway.	Lower	panel:	boxplot	of	expression	levels	of	CYP2C8	and	CYP2C19	(both	from	the	CYP2C	gene	cluster	on	chromosome	10,	UGT2A3	and	the	total	 expression	of	UGT2B	 genes	 (from	 the	UGT2	gene	 cluster	 on	 chromosome	4,	 expressed	 in	fragments	 per	 kilobase	million	 (FPKM)	 units.	 In	 all	 panels,	 boxplot	 centre	 line	 represents	 the	median	and	box	bounds	represent	 the	 inter-quartile	 range	(IQR).	The	whiskers	span	a	1.5-fold	IQR	or	the	highest	and	lowest	observation	values	if	they	extend	no	further	than	the	1.5-fold	IQR..	Source	 data	 are	 provided	 in	 Supplementary	 Tables	 1,	 4,	 9,	 and	 in	 the	 European	 Genome-phenome	Archive.			
Figure	5.	Molecular	groups	of	pulmonary	carcinoids.	A)	Heatmaps	of	the	expression	of	core	differentially	 expressed	 genes	 of	 each	 molecular	 cluster,	 i.e.,	 genes	 that	 are	 differentially	expressed	in	all	pairwise	comparisons	between	a	focal	cluster	and	the	other	clusters.	Green	bars	at	the	right	of	each	heatmap	indicate	a	significant	negative	correlation	with	the	methylation	level	of	at	least	one	CpG	site	from	the	gene	promoter	region.	The	color	scale	depends	on	the	range	of	q-value	 (q)	 and	 correlation	 estimate	 squared	 (R²)	 of	 the	 correlation	 test.	 B)	 Boxplots	 of	 the	expression	levels	of	selected	cancer-relevant	core	genes,	in	fragment	per	kilobase	million	(FPKM)	units,	where	centre	line	represents	the	median	and	box	bounds	represent	the	inter-quartile	range	(IQR).	 The	whiskers	 span	 a	 1.5-fold	 IQR	 or	 the	 highest	 and	 lowest	 observation	 values	 if	 they	extend	no	further	than	the	1.5-fold	IQR.	C)	Characteristic	hallmarks	of	cancer	in	each	molecular	cluster	 (Carcinoid	 A1	 without	 the	 supra-carcinoids,	 A2,	 and	 B),	 LCNEC	 and	 SCLC.	 Coloured	concentric	circles	correspond	to	the	molecular	clusters.	For	each	cluster,	dark	colours	highlight	significantly	 enriched	 hallmarks	 (Fisher’s	 exact	 test	 q-value	 <0.05).	 The	 mutated	 genes	contributing	to	a	given	hallmark	are	listed	in	the	boxes.	Recurrently	mutated	genes	are	indicated	in	brackets	by	the	number	of	samples	harbouring	a	mutation.	D)	Survival	analysis	of	pulmonary	carcinoids	 based	 on	 the	 expression	 level	 of	 eight	 core	 genes	 of	 cluster	 Carcinoid	B.	 The	 genes	were	 selected	 using	 a	 regularized	 GLM	 on	 expression	 data.	 For	 each	 gene,	 coloured	 lines	correspond	to	the	Kaplan-Meier	curve	of	overall	survival	for	individuals	with	a	high	(green)	and	low	 (orange)	 expression	 level	of	 this	 gene.	Cut-offs	 for	 the	 two	groups	were	determined	using	maximally	 selected	 rank	 statistics	 (Methods).	 The	 percentage	 of	 samples	 in	 each	 group	 is	represented	above	each	Kaplan-Meier	curve	and	the	logrank	test	p-value	is	given	in	bottom	right	for	each	gene.	Source	data	are	provided	 in	Supplementary	Tables	5,	10,	and	 in	 the	European	Genome-phenome	Archive.		
	
Figure	6.	Main	molecular	and	clinical	characteristics	of	 lung	neuroendocrine	neoplasms.	Upper	panel:	Radar	 charts	 of	 the	 expression	 level	 (z-score)	 of	 the	 characteristic	 genes	 (DLL3,	
ASCL1,	 ROBO1,	 SLIT1,	 ANGPTL3,	 ERBB4,	 UGT	 genes	 family,	 OTP,	 NKX2-1,	 PD-L1	 (CD274),	 and	other	 immune	 checkpoint	 genes)	 of	 each	 LNET	molecular	 cluster	 (Carcinoid	A1,	 Carcinoid	A2,	and	 B	 clusters),	 supra-ca,	 LCNEC	 and	 SCLC.	 The	 coloured	 text	 lists	 relevant	 characteristics—additional	molecular,	histopathological,	and	clinical	data—of	each	group.	Lower	panel:	heatmap	
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of	 the	 expression	 level	 (z-score)	 of	 the	 characteristic	 genes	 of	 each	 group	 from	 the	 left	 panel,	expressed	in	z-scores.	Source	data	are	provided	in	the	European	Genome-phenome	Archive.			
Tables	
	
Table	1.	Characteristics	of	supra-carcinoids.	FPKM	refers	to	Fragments	Per	Kilo-base	per	Million	reads.	The	median	FPKM	of	immune	checkpoint	(IC)	genes	was	calculated	based	on	the	genes	included	in	Figure	
2E,	excluding	HLA	genes	because	of	their	very	large	expression	levels	
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